Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
  • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
  • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H1/00—Processes for the preparation of sugar derivatives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Definitions

• Streptococcus pneumonia infections can transmit genes coding for antibiotic resistance both vertically (to their progeny) and horizontally (to neighboring bacteria of different lineages), and as a result antibiotic resistance can evolve quickly, particularly in nosocomial (hospital) settings. See, e.g., Wright, Chem. Commun. (2011) 47:4055-4061. This year, >99,000 people will die in the U.S. from healthcare-associated infections, more than all casualties from car accidents, HIV, and breast cancer combined, creating an estimated burden of up to $45 billion in U.S. healthcare costs. See, e.g., Klevens et al., Public Health Rep (2007) 122:160-166.
• the macrolides are one of the few major clinically important classes of antibiotics for which the only practical access has been through semi ⁇ synthesis, or chemical
• erythromycin is known to undergo acid-promoted internal ketalization (cyclization of the C6 and C12 hydroxyl groups onto the C9 ketone) in the gut, which leads to adverse
• Second-generation macrolide antibiotics clarithromycin and azithromycin addressed issues of acid instability and were prepared semi-synthetically in 4-6 steps from erythromycin, which is readily available through large-scale fermentation. See, e.g., Ma et al., Curr. Med. Chem. (2011) 18:1993- 2015; Wu et al., Curr. Pharm. Des. (2000) 6:181-223; Ma et al., Mini-Rev. Med. Chem. (2010) 10:272-286; Asaka et al., Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) (2003) 3:961-989; Morimoto et al., J. Antibiot. (1990) 43:286-294; Morimoto et al., J.
• Azithromycin has been shown to exhibit markedly improved efficacy against Gram ⁇ negative organisms, and has a longer half-life and higher tissue distribution than the other macrolide antibiotics, thought to correlate with its 15-membered ring containing a tertiary amine. See, e.g., Ferwerda et al., J. Antimicrob. Chemother. (2001) 47:441-446; Girard et al., Antimicrob. Agents Chemother. (1987) 31:1948-1954.
• the natural product tylosin a 16-membered macrolide used in veterinary medicine, has been shown by X-ray crystallography to occupy the same binding pocket as erythromycin and azithromycin, suggesting that there is a high tolerance for variability in ring size and composition of the macrocycle.
• Ketolides such as telithromycin and solithromycin defeat the efflux mechanism of resistance by replacement of the C3 cladinose sugar with a carbonyl group (hence the name“ketolides”), and are thought to exhibit greatly increased binding by virtue of favorable interactions between the novel aryl-alkyl sidechain and the ribosome.
• ketolides such as telithromycin and solithromycin have not addressed several of the newest forms of macrolide resistance that have evolved in nosocomial settings, especially ribosome methylation and RNA point mutations.
• Macrolides are an important class of antibiotics, and have proven to be safe and effective in the treatment of infectious diseases for decades.
• a critical component of erythromycin, and many other macrolide antibiotics e.g., azithromycin, carbomycin, cethromycin, clarithromycin, roxithromycin, solithromycin, telithromycin, tylosin
• the desosamine or mycaminose sugar at the C5 position of the macrolide is the desosamine or mycaminose sugar at the C5 position of the macrolide.
• the C5 sugar is D-desosamine.
• the C3 postion and/or C6 position of the sugar can be modified to afford novel macrolide antibiotics.
• the compounds described herein comprise macrolides with a modified sugar (e.g., desosamine and mycaminose) at the C5 position of the macrolide.
• the sugar at the C5 position of the macrolide is modified at the C6 postion of the sugar.
• Such compounds are provided as macrolides of Formula (I):
• the present invention provides compounds which are macrolides with a modified sugar moiety, wherein the sugar is modified at the C3 position of the sugar (e.g., the amine moiety of desosamine or mycaminose).
• a modified sugar moiety wherein the sugar is modified at the C3 position of the sugar (e.g., the amine moiety of desosamine or mycaminose).
• Such compounds are provided as macrolides of Formula (I-N):
• the invention provides 14-membered ketolides of Formula (I-a) and 14-, 15-, and 16-membered azaketolides of Formulae (I-b), (I-c), and (I-d), respectively, as described herein.
• the invention provides 14-membered ketolides of Formula (I- a-N) and 14-, 15-, and 16-membered azaketolides of Formulae (I-b-N), (I-c-N), and (I-d-N), respectively, as described herein:
• the macrolides of the invention have anti-microbial activity and may be used to treat and/or prevent infectious diseases and inflammatory conditions.
• Pharmaceutical compositions of the compounds, and methods of treatment using the compounds or compositions thereof are provided herein.
• Infectious diseases which may be treated with a compound of the invention include, but are not limited to, bacterial infections caused by Staphylococcus, Bacillus, Strepococcus, Escherichia, and Haemophilus species.
• Methods of preparing macrolides with modified C5 sugars are also provided herein.
• the general synthetic methodology involves construction of eastern and western halves of the macrolide, and coupling of the eastern and western halves followed by macrocyclization. Variation of macrolide substituents may be accomplished at any stage of the synthesis (e.g., during synthesis of the two halves, after coupling, or after macrocyclization), and many positions may be varied independently to access a diverse range of macrolides.
• the modified sugar moiety (e.g., desosamine or mycaminose analog) is typically installed during synthesis of the eastern half, for example, via the glycosylation of a hydroxyl group at the C5 position with the desired glycosyl donor (e.g., a thioglycoside sugar).
• the sugar may also be attached at other stages of the synthesis, for example, after assembly of the macrolide by deprotecting a C5 hydroxyl and treating the macrolide with a glycosyl donor.
• the invention also provides intermediates in the preparation of the macrolides described herein.
• Figure 1 depicts exemplary 14-, 15-, and 16-membered macrolide antibiotics.
• Figure 2 depicts the crystal structure of solithromycin bound to a ribosome of E. coli. Residues in a 12- ⁇ sphere generated using MacPyMol from PDB #3ORB. See, e.g., Llano-Sotelo Antimicrob. Agents Chemother. (2010) 54:4961-4970. D ETAILED D ESCRIPTION OF C ERTAIN E MBODIMENTS
• the macrolides specifically described herein include 14-membered ketolides, 14-membered azaketolides, 15-membered azaketolides, and 16-membered azaketolides.
• Ketolides are typically connected between C8 and C10 with a ketone.
• Azaketolides feature an amine, or aminoalkylene fragment in place of the keto group.
• the invention provides macrolides with modified sugars at the C5 position of the macrolide (e.g., desosamine or mycaminose analogs), wherein the sugar is modified at the C6 position of the sugar.
• the invention provides compounds of Formula (I):
• R B is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
• L S2 is a bond, ⁇ NR S ⁇ , ⁇ O ⁇ , or ⁇ S ⁇ , or a linking group selected from the group consisting of optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, and optionally substituted heteroalkynylene, and combinations thereof;
• each R S is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a nitrogen protecting group when attached to a nitrogen atom, or a sulfur protecting group when attached to a sulfur atom, or two R S groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or heteroaryl ring;
• each of R S4a and R S4b is independently hydrogen, halogen, optionally substituted C 1 -C 6 alkyl, or ⁇ OR SO4 ;
• each of R S6a and R S6b is independently hydrogen, halogen, or optionally substituted C 1 -C 6 alkyl;
• each R SN is independently hydrogen, optionally substituted C 1 -C 6 alkyl, or a nitrogen protecting group, or two R SN groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or heteroaryl ring;
• each of R SO and R SO4 is independently hydrogen, optionally substituted C 1 -C 6 alkyl, a carbohydrate, or an oxygen protecting group;
• each of R 1a and R 1b is independently hydrogen, halogen, acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each of R 2a and R 2b is independently hydrogen, halogen, optionally substituted alkyl, or optionally substituted alkenyl;
• each of R 3 and R 4 is independently hydrogen, halogen, optionally substituted alkyl,
• each R 3a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an oxygen protecting group, or of formula:
• each L C3 is independently a bond, or is a linking group selected from the group consisting of optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted heteroalkenylene, and optionally substituted heteroalkynylene, and combinations thereof;
• each A 3 is independently optionally substituted carbocyclyl, optionally substituted
• heterocyclyl optionally substituted aryl, or optionally substituted heteroaryl
• each of R 5a and R 5b is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl;
• R 6 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl,
• optionally substituted alkynyl optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;
• R 10 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;
• R 7 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R 8 is hydrogen, halogen, or optionally substituted C 1 -C 6 alkyl.
• R 14 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or of formula:
• L C1 is a bond, or a linking group selected from the group consisting of optionally
• substituted alkylene optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted
• heteroalkenylene and optionally substituted heteroalkynylene, and combinations thereof;
• A is ⁇ NH ⁇ , ⁇ NH ⁇ NH ⁇ , ⁇ NH ⁇ O ⁇ , ⁇ O ⁇ NH ⁇ , ⁇ S ⁇ , ⁇ SS ⁇ , ⁇ O ⁇ , or of formula:
• Q is ⁇ NH ⁇ , ⁇ NH ⁇ NH ⁇ , ⁇ O ⁇ NH ⁇ , ⁇ NH ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ O ⁇ ;
• L C2 is a bond, or a linking group selected from the group consisting of optionally
• substituted alkylene optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted
• heteroalkenylene and optionally substituted heteroalkynylene, and combinations thereof;
• R W1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
• each R W2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or two R W2 groups are joined to form an optionally substituted cyclic moiety;
• R 23 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R Z8 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R Z8 groups attached to the same nitrogen atom are joined to form an optionally
• the compound of Formula (I) is not of the formula:
• R A is a non-hydrogen group.
• R S is not alkenyl.
• any formulae described herein are also meant to include salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof.
• the provided compound is a salt of any of the formulae described herein.
• the provided compound is a pharmaceutically acceptable salt of any of the formulae described herein.
• the provided compound is a solvate of any of the formulae described herein.
• the provided compound is a hydrate of any of the formulae described herein.
• the provided compound is a polymorph of any of the formulae described herein.
• the provided compound is a co-crystal of any of the formulae described herein. In certain embodiments, the provided compound is a tautomer of any of the formulae described herein. In certain embodiments, the provided compound is a stereoisomer of any of the formulae described herein. In certain embodiments, the provided compound is of an isotopically labeled form of any of the formulae described herein. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, replacement of 19 F with 18 F, or the replacement of a 12 C by a 13 C or 14 C are within the scope of the disclosure. In certain embodiments, the provided compound is a deuterated form of any of the formulae described herein.
• the compound of Formula (I) is a compound of Formula (I- a):
• the compound of Formula (I) is a compound of Formula (I- b):
• the compound of Formula (I) is a compound of Formula (I- c):
• the compound of Formula (I) is a compound of Formula (I- d):
• the compound of Formula (I) is a compound of Formula (I- e):
• the compound of Formula (I) is a compound of Formula (II-a):
• R 1a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 10 , L C1 , R 23 , X, R A , R S4a , R S4b , R SN , and R SO are as described herein.
• the compound of Formula (I) is a compound of Formula (II-b):
• the compound of Formula (I) is a compound of Formula (II-c):
• R 1a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 10 , L C1 , R 23 , X, R A , R S4a , R S4b , R SN , R SO , and R Z2 are as described herein.
• the compound of Formula (I) is a compound of Formula (II-d):
• the compound of Formula (I) is a compound of Formula (II-e):
• R 1a , R 2b , R 4 , R 5a , R 5b , R 6 , R 7 , R 10 , R 14a , X, R A , R S4a , R S4b , R SN , R SO , R Z2 , and A 3 are as described herein.
• the compound of Formula (I) is a compound of Formula (III-a):
• the compound of Formula (I) is a compound of Formula (III-b):
• R 1a , R 3a , R 5a , R 5b , R 6 , R 10 , L C1 , R 23 , X, R A , R S4b , R SO , and R Z2 are as described herein.
• the compound of Formula (I) is a compound of Formula (III-c):
• the compound of Formula (I) is a compound of Formula (III-d):
• R 1a , R 3a , R 5a , R 5b , R 6 , R 10 , L C1 , R 23 , X, R A , R S4b , R SO , and R Z2 are as described herein.
• the compound of Formula (I) is a compound of Formula (III-e):
• R 1a , R 5a , R 5b , R 6 , R 10 , R 14a , X, R A , R S4b , R S6a , R S4b , R SO , R Z2 , and A 3 are as described herein.
• the present invention provides macrolides comprising sugars (e.g., desosamine or mycaminose analogs), wherein the sugar is modified at the C3 positon of the sugar (e.g., the dimethylamino moiety of desosamine or mycaminose).
• sugars e.g., desosamine or mycaminose analogs
• the sugar is modified at the C3 positon of the sugar (e.g., the dimethylamino moiety of desosamine or mycaminose).
• the invention provides macrolides which are compounds of Formula (I-N):
• R Z2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, acyl, or a nitrogen protecting group;
• R B is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
• L S2 is a bond, ⁇ NR S ⁇ , ⁇ O ⁇ , or ⁇ S ⁇ , or a linking group selected from the group consisting of optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, and optionally substituted heteroalkynylene, and combinations thereof;
• each R S is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a nitrogen protecting group when attached to a nitrogen atom, or a sulfur protecting group when attached to a sulfur atom, or two R S groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or heteroaryl ring;
• each of R S4a and R S4b is independently hydrogen, halogen, optionally substituted C 1 -C 6 alkyl, or ⁇ OR SO4 ;
• each instance of R S5a and R S5b is independently hydrogen, halogen, optionally substituted C 1 -C 6 alkyl,–OR SO5 , or of the formula:
• each instance of R S6a and R S6b is independently hydrogen, halogen, or optionally
• each R SN1 is independently hydrogen, optionally substituted C 1 -C 6 alkyl, optionally
• heterocyclyl optionally substituted heteroaryl, optionally substituted acyl, or a nitrogen protecting group, or optionally two R SN1 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring;
• each of R SO , R SO4 , and R SO5 is independently hydrogen, optionally substituted C 1 -C 6
• alkyl a carbohydrate, or an oxygen protecting group
• each of R 1a and R 1b is independently hydrogen, halogen, acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each of R 2a and R 2b is independently hydrogen, halogen, optionally substituted alkyl, or optionally substituted alkenyl;
• each of R 3 and R 4 is independently hydrogen, halogen, optionally substituted alkyl,
• each R 3a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an oxygen protecting group, or of formula:
• each L C3 is independently a bond, or is a linking group selected from the group consisting of optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted heteroalkenylene, and optionally substituted heteroalkynylene, and combinations thereof;
• each A 3 is independently optionally substituted carbocyclyl, optionally substituted
• heterocyclyl optionally substituted aryl, or optionally substituted heteroaryl
• each of R 5a and R 5b is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl;
• R 6 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;
• R 10 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroaralkyl;
• R 7 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R 8 is hydrogen, halogen, or optionally substituted C 1 -C 6 alkyl.
• R 14 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or of formula:
• L C1 is a bond, or a linking group selected from the group consisting of optionally
• substituted alkylene optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted
• heteroalkenylene and optionally substituted heteroalkynylene, and combinations thereof;
• A is ⁇ NH ⁇ , ⁇ NH ⁇ NH ⁇ , ⁇ NH ⁇ O ⁇ , ⁇ O ⁇ NH ⁇ , ⁇ S ⁇ , ⁇ SS ⁇ , ⁇ O ⁇ , or of formula:
• Q is ⁇ NH ⁇ , ⁇ NH ⁇ NH ⁇ , ⁇ O ⁇ NH ⁇ , ⁇ NH ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ O ⁇ ;
• L C2 is a bond, or a linking group selected from the group consisting of optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted
• heteroalkenylene and optionally substituted heteroalkynylene, and combinations thereof;
• R W1 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
• each R W2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or two R W2 groups are joined to form an optionally substituted cyclic moiety;
• R 23 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and each R Z8 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R Z8 groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;
• At least one instance of R SN1 is not methyl.
• at least one instance of R SN1 is not methyl.
• both instances of R SN1 are not methyl.
• one instance of R SN1 is not methyl.
• at least one instance of R SN1 is not unsubstituted C 1 -C 3 alkyl.
• both instances of R SN1 are not unsubstituted C 1 -C 3 alkyl.
• at least one instance of R SN1 is not unsubstituted C 1 -C 6 alkyl.
• both instances of R SN1 are not unsubstituted C 1 -C 6 alkyl.
• At least one instance of R SN1 is not hydrogen. In certain embodiments, both instances of R SN1 are not hydrogen.
• At least one of R SN1 is not benzyl (–CH 2 - phenyl). In certain embodiments, both R SN1 are not benzyl (–CH 2 -phenyl). In certain embodiments, at least one instance of R SN1 is not tert-butyloxycarbonyl. In certain embodiments, if one instance of R SN1 is tert-butyloxycarbonyl (Boc), the other instance is not hydrogen. In certain embodiments, if one instance of R SN1 is hydrogen, the other instance is not tert-butyloxycarbonyl (Boc). In certain embodiments, one instance of R SN1 is not tert- butyloxycarbonyl (Boc), and the other instance is not hydrogen.
• the compound of Formula (I-N) is a compound of Formula (I-a-N):
• R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 10 , R 14 , R S4a , R S4b , R S5a , R S5b , R SN1 , and R SO are as described herein.
• the compound of Formula (I-N) is a compound of Formula (I-b-N):
• the compound of Formula (I-N) is a compound of Formula (I-c-N):
• R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 10 , R 14 , R S4a , R S4b , R S5a , R S5b , R SN1 , R SO , and R Z2 are as described herein.
• the compound of Formula (I-N) is a compound of Formula (I-d-N):
• the compound of Formula (I-N) is a compound of Formula (I-e-N):
• R 1a , R 1b , R 2a , R 2b , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 10 , R 14a , R S4a , R S4b , R S5a , R S5b , R SN1 , R SO , R Z2 , L C3 , and A 3 are as described herein.
• the compound of Formula (I-N) is a compound of Formula (II-a-N):
• the compound of Formula (I-N) is a compound of Formula (II-b-N):
• the compound of Formula (I-N) is a compound of Formula (II-c-N):
• the compound of Formula (I-N) is a compound of Formula (II-d-N):
• the compound of Formula (I-N) is a compound of Formula (II-e-N):
• the compound of Formula (I-N) is a compound of Formula (III-a-N):
• R 1a , R 3a , R 5a , R 5b , R 6 , R 10 , L C1 , R 23 , X, R A , R S4b , R S5a , R SN1 , and R SO are as described herein.
• the compound of Formula (I-N) is a compound of Formula (III-b-N):
• the compound of Formula (I-N) is a compound of Formula (III-c-N):
• R 1a , R 3a , R 5a , R 5b , R 6 , R 10 , L C1 , R 23 , X, R A , R S4b , R SO , and R Z2 are as described herein.
• the compound of Formula (I-N) is a compound of Formula (III-d-N):
• the compound of Formula (I-N) is a compound of Formula (III-d-N-2):
• R 1a , R 3a , R 5a , R 5b , R 6 , R 10 , L C1 , R 23 , X, R A , R S4b , R S5a , R SO , R SN1 , and R Z2 are as described herein.
• the compound of Formula (I-N) is a compound of Formula (III-e-N):
• Attached to group Z is a methylene (i.e., ⁇ CH 2 ⁇ ) group, which may be repeated 0, 1, or 2 times, according to variable p.
• Z is ⁇ NR Z2 ⁇ , and p is 0, e.g., to give a 14-membered azaketolide.
• Z is ⁇ NR Z2 ⁇ , and p is 1, e.g., to give a 15-membered azaketolide. In certain embodiments, Z is ⁇ NR Z2 ⁇ , and p is 2, e.g., to give a 16-membered azaketolide. In certain embodiments, Z is ⁇ NH ⁇ , and p is 0. In certain embodiments, Z is ⁇ NH ⁇ , and p is 1. In certain embodiments, Z is ⁇ NH ⁇ , and p is 2.
• R Z2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, acyl, or a nitrogen protecting group. In certain embodiments, R Z2 is hydrogen.
• R Z2 is acyl. In certain embodiments, R Z2 is an aldehyde ( ⁇ CHO). In certain embodiments R Z2 is a nitrogen protecting group.
• R Z2 is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl optionally substituted C 1-2 alkyl, optionally substituted C 2-3 alkyl, optionally substituted C 3-4 alkyl, optionally substituted C 4-5 alkyl, or optionally substituted C 5- 6 alkyl.
• R Z2 is ⁇ CH 3 .
• R Z2 is alkyl substituted with one or more halogen atoms, e.g., optionally substituted haloalkyl; e.g., ⁇ CF 3 , ⁇ CF 2 CF 3 , or ⁇ CF 2 H.
• R Z2 is ⁇ CH 2 CHO.
• R Z2 is optionally substituted carbocyclyl, e.g., optionally substituted C 3-6 carbocyclyl, optionally substituted C 3-4 carbocyclyl, optionally substituted C 4-5 carbocyclyl, or optionally substituted C 5-6 carbocyclyl.
• R Z2 is optionally substituted heterocylyl, e.g., optionally substituted 3-6 membered heterocyclyl.
• R Z2 is optionally substituted aryl, e.g., optionally substituted phenyl.
• R Z2 is optionally substituted heteroaryl, e.g., optionally substituted 5- to 6-membered heteroaryl.
• X is ⁇ NH ⁇ . In certain embodiments, X is ⁇ O ⁇ .
• R B may be hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or nitrogen protecting group.
• R S is hydrogen, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group.
• R A is hydrogen.
• R A is optionally substituted alkyl.
• R A is optionally substituted C 1 -C 6 alkyl.
• R A is C 1 -C 6 alkyl.
• RA is optionally substituted alkenyl, e.g., C 2 -C 6 alkenyl.
• R A is methyl. In some embodiments, R A is ethyl, propyl, or butyl. In some embodiments, R A is optionally substituted alkenyl. In some embodiments, R A is optionally substituted alkynyl. In some embodiments, R A is optionally substituted carbocyclyl. In some embodiments, R A is optionally substituted heterocyclyl. In some embodiments, R A is optionally substituted aryl. In some embodiments, R A is optionally substituted heteroaryl. In some embodiments, R A is a nitrogen protecting group.
• R SN2 may be hydrogen, optionally substituted C 1 -C 6 alkyl, or a nitrogen protecting group.
• R SN2 is hydrogen.
• R SN2 is optionally substituted C 1 -C 6 alkyl.
• R SN2 is C 1 -C 6 alkyl. In some embodiments, R SN2 is methyl. In some embodiments, R SN2 is ethyl, propyl, or butyl. In some embodiments, R SN2 is a nitrogen protecting group.
• R A is hydrogen. In some embodiments, R A is optionally substituted alkyl. In some embodiments, R A is optionally substituted C 1 -C 6 alkyl. In some embodiments, R A is C 1 -C 6 alkyl. In some embodiments, RA is optionally substituted alkenyl, e.g., C 2 -C 6 alkenyl. In some
• R A is methyl. In some embodiments, R A is ethyl, propyl, or butyl. In some embodiments, R A is optionally substituted alkenyl. In some embodiments, R A is optionally substituted alkynyl. In some embodiments, R A is optionally substituted carbocyclyl. In some embodiments, R A is optionally substituted heterocyclyl. In some embodiments, R A is optionally substituted aryl. In some embodiments, R A is optionally substituted heteroaryl. In some embodiments, R A is an oxygen protecting group.
• R SN2 may be hydrogen, optionally substituted C 1 -C 6 alkyl, or a nitrogen protecting group.
• R SN2 is hydrogen.
• R SN2 is optionally substituted C 1 -C 6 alkyl.
• R SN2 is C 1 -C 6 alkyl. In some embodiments, R SN2 is methyl. In some embodiments, R SN2 is ethyl, propyl, or butyl. In some embodiments, R SN2 is a nitrogen protecting group.
• R A may include L S2 .
• L S2 may be a bond, ⁇ NR S ⁇ , ⁇ O ⁇ , or ⁇ S ⁇ , or a linking group selected from optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted heteroalkynylene, and combinations thereof.
• L S2 is absent, ⁇ NR S ⁇ , ⁇ O ⁇ , or ⁇ S ⁇ .
• L S2 is a bond.
• L S2 is ⁇ NR S ⁇ .
• L S2 is ⁇ O ⁇ .
• L S2 is ⁇ S ⁇ .
• L S2 is optionally substituted alkylene. In some embodiments, L S2 is optionally substituted alkenylene. In some embodiments, L S2 is optionally substituted alkynylene. In some embodiments, L S2 is optionally substituted heteroalkylene. In some embodiments, L S2 is ⁇ CH 2 NH ⁇ , ⁇ CH 2 NMe ⁇ , ⁇ CH 2 O ⁇ , ⁇ CH 2 CH 2 NH ⁇ , ⁇ CH 2 CH 2 NMe ⁇ , or ⁇ CH 2 CH 2 O ⁇ . In some embodiments, L S2 is optionally substituted heteroalkenylene. In some embodiments, L S2 is optionally substituted
• R A may include one or more R S .
• R S may be independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a nitrogen protecting group when attached to a nitrogen atom, or a sulfur protecting group when attached to a sulfur atom, or two R S groups attached to the same nitrogen atom may be joined to form an optionally substituted heterocyclyl or heteroaryl ring.
• R S is hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen, oxygen, or sulfur protecting group.
• R S is hydrogen.
• R S is optionally substituted alkyl.
• R S is optionally substituted C 1 -C 6 alkyl.
• R S is C 1 -C 6 alkyl.
• R A is methyl.
• R A is ethyl, propyl, or butyl.
• R S is optionally substituted alkenyl.
• R S is optionally substituted alkynyl. In some embodiments, R S is optionally substituted carbocyclyl. In some embodiments, R S is optionally substituted heterocyclyl. In some embodiments, R S is optionally substituted aryl. In some embodiments, R S is optionally substituted heteroaryl. In some embodiments, R S is a nitrogen protecting group. In some embodiments, R S is an oxygen protecting group. In some embodiments, R S is a sulfur protecting group. In some
• two R S are joined to form a heterocyclyl ring. In some embodiments, two R S are joined to form a heteroaryl ring.
• R B is hydrogen, optionally substituted alkyl, or a nitrogen protecting group. In some embodiments, R B is hydrogen. In some embodiments, R B is optionally substituted alkyl. In some embodiments, R B is optionally substituted C 1 -C 6 alkyl. In some embodiments, R B is C 1 -C 6 alkyl. In some embodiments, R B is methyl. In some embodiments, R B is ethyl, propyl, or butyl. In some embodiments, R B is optionally substituted alkenyl. In some embodiments, R B is optionally substituted alkynyl. In some embodiments, R B is optionally substituted carbocyclyl. In some embodiments, R B is optionally substituted heterocyclyl. In some embodiments, R B is optionally substituted aryl. In some embodiments, R B is optionally substituted heteroaryl. In some embodiments, R B is a nitrogen protecting group.
• X is ⁇ O ⁇
• R A is hydrogen, optionally substituted alkyl, or an oxygen protecting group.
• substituent ⁇ XR A is:
• X is ⁇ NR B ⁇
• each of R A and R B is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group.
• substituent ⁇ XR A is:
• substituent ⁇ XR A is:
• substituent ⁇ XR A is:
• substituent ⁇ XR A is:
• R A and R B are taken together to form an optionally substituted heterocyclyl ring e.g., optionally substituted 3-6 membered heterocyclyl.
• X is ⁇ NR B ⁇ and, R A and R B are taken together to form an optionally substituted heteroaryl ring, e.g., optionally substituted 5- to 6-membered heteroaryl. In some embodiments, X is ⁇ NR B ⁇ and, R A and R B are taken together to form an optionally substituted 5-membered heteroaryl. In some embodiments, X is ⁇ NR B ⁇ and, R A and R B are taken together to form an optionally substituted triazole. In some embodiments, the substituent ⁇ XR A is of formula: ,
• R 23 is as defined herein.
• R 23 is selected from any one of the following aryl or heteroaryl ring systems: .
• Groups R S6a and R S6b are selected from any one of the following aryl or heteroaryl ring systems: .
• R S6a and R S6b may independently be hydrogen, halogen, or optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S6a and R S6b are hydrogen. In certain embodiments, R S6a and R S6b are halogen. In certain embodiments, R S6a and R S6b are optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S6a and R S6b are C 1 -C 6 alkyl. In certain embodiments, R S6a is hydrogen, and R S6b is halogen. In certain embodiments, R S6a is hydrogen, and R S6b optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S6a is hydrogen, and R S6b C 1 -C 6 alkyl. In some embodiments, R S6a is hydrogen. In some embodiments, R S6a is hydrogen. In some embodiments, R S6a and R S6b are hydrogen. In some embodiments, R S6a is
• R S6a is ⁇ F. In some embodiments, R S6a is ⁇ Cl, ⁇ Br, or ⁇ I. In some
• R S6a is optionally substituted alkyl. In some embodiments, R S6a is optionally substituted C 1 -C 6 alkyl. In some embodiments, R S6a is C 1 -C 6 alkyl. In some embodiments, R S6a is methyl. In some embodiments, R S6a is ethyl, propyl, or butyl. In some embodiments, R S6b is hydrogen. In some embodiments, R S6b is ⁇ F. In some embodiments, R S6b is ⁇ Cl, ⁇ Br, or ⁇ I. In some embodiments, R S6b is optionally substituted alkyl. In some embodiments, R S6b is optionally substituted C 1 -C 6 alkyl.
• R S6b is C 1 -C 6 alkyl. In some embodiments, R S6b is methyl. In some embodiments, R S6b is ethyl, propyl, or butyl. In certain embodiments, R S6a is methyl, and R S6b is hydrogen. In certain embodiments, R S6b is methyl, and R S6a is hydrogen. In certain embodiments, the carbon to which R S6a and R S6b are attached is a stereocenter of the (R)-configuration. In certain embodiments, the carbon to which R S6a and R S6b are attached is a stereocenter of the (S)-configuration. Groups R S4a and R S4b
• each of R S4a and R S4b may independently be hydrogen, halogen, optionally substituted C 1 -C 6 alkyl, or ⁇ OR SO4 .
• R S4a and R S4b are hydrogen.
• R S4a and R S4b are halogen.
• R S4a and R S4b are optionally substituted C 1 -C 6 alkyl.
• R S4a and R S4b are C 1 -C 6 alkyl.
• R S4a is hydrogen, and R S4b is halogen.
• R S4a is hydrogen, and R S4b is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S4a is hydrogen, and R S4b is C 1 -C 6 alkyl. In certain embodiments, R S4a is hydrogen, and R S4b is ⁇ OR SO4 . In certain embodiments, R S4b is hydrogen, and R S4a is halogen. In certain embodiments, R S4b is hydrogen, and R S4a is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S4b is hydrogen, and R S4a is C 1 -C 6 alkyl. In certain embodiments, R S4b is hydrogen, and R S4a is ⁇ OR SO4 .
• R S4A is hydrogen. In some embodiments, R S4A is ⁇ F. In some embodiments, R S4a is ⁇ Cl, ⁇ Br, or ⁇ I. In some embodiments, R S4a is optionally substituted alkyl. In some embodiments, R S4a is optionally substituted C 1 -C 6 alkyl. In some
• R S4a is C 1 -C 6 alkyl. In some embodiments, R S4a is methyl. In some
• R S4a is ethyl, propyl, or butyl. In certain embodiments, R S4a is ⁇ OR SO4 . In certain embodiments, R S4a is ⁇ OH. In certain embodiments, R S4a is ⁇ OR SO4 , and R SO4 is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S4a is ⁇ OR SO4 , and R SO4 is a carbohydrate. In certain embodiments, R S4a is ⁇ OR SO4 , and R SO4 is a monosaccharide. In certain embodiments, R S4a is ⁇ OR SO4 , and R SO4 is an oxygen protecting group. In some embodiments, R S4b is hydrogen.
• R S4b is ⁇ F. In some embodiments, R S4b is ⁇ Cl, ⁇ Br, or ⁇ I. In some embodiments, R S4b is optionally substituted alkyl. In some embodiments, R S4b is optionally substituted C 1 -C 6 alkyl. In some embodiments, R S4b is C 1 -C 6 alkyl. In some embodiments, R S4b is methyl. In some embodiments, R S4b is ethyl, propyl, or butyl. In certain embodiments, R S4b is ⁇ OR SO4 . In certain embodiments, R S4b is ⁇ OH.
• R S4b is ⁇ OR SO4 , and R SO4 is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S4b is ⁇ OR SO4 , and R SO4 is a carbohydrate. Groups R S5a and R S5b
• each of R S5a and R S5b are independently hydrogen, halogen, optionally substituted C 1 -C 6 alkyl, ⁇ OR SO5 , or of the formula: .
• R S5b is hydrogen, and R S5a is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S5b is hydrogen, and R S5a is unsubstituted C 1 -C 6 alkyl. In certain embodiments, R S5b is hydrogen, and R S5a is optionally substituted C 1 -C 3 alkyl. In certain embodiments, R S5b is hydrogen, and R S5a is unsubstituted C 1 -C 3 alkyl.
• R S5b is hydrogen, and R S5a is ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl. In certain embodiments, R S5b is hydrogen, and R S5a is methyl.
• R S5a is hydrogen, and R S5b is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S5a is hydrogen, and R S5b is unsubstituted C 1 -C 6 alkyl. In certain embodiments, R S5a is hydrogen, and R S5b is optionally substituted C 1 -C 3 alkyl. In certain embodiments, R S5a is hydrogen, and R S5b is unsubstituted C 1 -C 3 alkyl.
• R S5a is hydrogen
• R S5b is ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl.
• R S5a is hydrogen
• R S5b is methyl.
• R S5a and R S5b are hydrogen. In certain embodiments, R S5a and R S5b are halogen. In certain embodiments, R S5a and R S5b are optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S5a and R S5b are unsubstituted C 1 -C 6 alkyl. In certain embodiments, R S5a and R S5b are optionally substituted C 1 -C 3 alkyl. In certain embodiments, R S5a and R S5b are unsubstituted C 1 -C 3 alkyl. In certain embodiments, R S5a and R S5b are each independently methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl.
• R S5a is optionally substituted alkyl. In some embodiments, R S5a is optionally substituted C 1 -C 6 alkyl. In some embodiments, R S5a is unsubstituted C 1 -C 6 alkyl. In some embodiments, R S5a is optionally substituted C 1 -C 3 alkyl. In some
• R S5a is unsubstituted C 1 -C 3 alkyl. In some embodiments, R S5a is methyl. In some embodiments, R S5a is ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl.
• R S5a is hydrogen. In some embodiments, R S5a is halogen. In some embodiments, R S5a is ⁇ F. In some embodiments, R S5a is ⁇ Cl, ⁇ Br, or ⁇ I. In certain embodiments, R S5a is ⁇ OR SO5 . In certain embodiments, R S5a is ⁇ OH. In certain embodiments, R S5a is ⁇ OR SO5 , and R SO5 is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S5a is ⁇ OR SO5 , and R SO5 is a carbohydrate. In certain embodiments, R S5a is ⁇ OR SO5 , and R SO5 is a monosaccharide. In certain embodiments, R S5a is ⁇ OR SO5 , and R SO5 is an oxygen protecting group.
• R S5b is optionally substituted alkyl. In some embodiments, R S5b is optionally substituted C 1 -C 6 alkyl. In some embodiments, R S5b is unsubstituted C 1 -C 6 alkyl. In some embodiments, R S5b is optionally substituted C 1 -C 3 alkyl. In some
• R S5b is unsubstituted C 1 -C 3 alkyl. In some embodiments, R S5b is methyl. In some embodiments, R S5b is ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl.
• R S5b is hydrogen. In some embodiments, R S5b is halogen. In some embodiments, R S5b is ⁇ F. In some embodiments, R S5b is ⁇ Cl, ⁇ Br, or ⁇ I. In certain embodiments, R S5b is ⁇ OR SO5 . In certain embodiments, R S5b is ⁇ OH. In certain embodiments, R S5b is ⁇ OR SO5 , and R SO5 is optionally substituted C 1 -C 6 alkyl. In certain embodiments, R S5b is ⁇ OR SO5 , and R SO5 is a carbohydrate.
• each instance of R SO5 is independently hydrogen, optionally substituted C 1 -C 6 alkyl, a carbohydrate, or an oxygen protecting group.
• R SO5 is hydrogen.
• R SO5 is optionally substituted C 1 -C 6 alkyl.
• R SO5 is a carbohydrate.
• R SO5 is an oxygen protecting group.
• R S5a is of the formula: .
• R S5b is of the formula: .
• R S5a is of the formula:
• R S5b is hydrogen.
• R S5a is of the formula:
• R S5b is of the formula:
• R S5b is hydrogen.
• R S5a is of the formula:
• R S5b is of the formula:
• R S5a is of the formula:
• R S5b is hydrogen.
• R S5a is of the formula:
• R S5b is of the formula:
• R S5a is of the formula:
• R S5b is hydrogen.
• Group R SN
• each R SN of the sugar substituent ⁇ N(R SN ) 2 may independently be hydrogen, optionally substituted C 1 -C 6 alkyl, or a nitrogen protecting group, or two R SN may be joined to form an optionally substituted heterocyclyl or heteroaryl ring.
• at least one R SN is hydrogen.
• both R SN are joined to form an optionally substituted heterocyclyl ring.
• both R SN are joined to form an optionally substituted heteroaryl ring.
• both R SN are C 1 -C 6 alkyl.
• both R SN are C 1 -C 6 alkyl.
• both R SN are methyl. In certain embodiments, both R SN are both ethyl, both propyl, or both butyl. In certain embodiments, both R SN are independently methyl, propyl, or butyl. In certain embodiments, both R SN are nitrogen protecting groups. In certain embodiments, both R SN are identical nitrogen protecting groups. In certain embodiments, one R SN is hydrogen, and the other R SN is optionally substituted C 1 -C 6 alkyl. In certain embodiments, one R SN is hydrogen, and the other R SN is C 1 -C 6 alkyl. In certain embodiments, one R SN is hydrogen, and the other R SN is methyl.
• one R SN is hydrogen, and the other R SN is ethyl, propyl, or butyl. In certain embodiments, R SN is hydrogen, and the other R SN is a nitrogen protecting group. In certain embodiments, one R SN is hydrogen, and the other R SN is benzyl. In certain embodiments, both R SN are benzyl. In certain embodiments, one R SN is hydrogen, and the other R SN is alkoxycarbonyl (e.g., methoxycarbonyl, tert-butylcarbonyl). In certain embodiments, R SN is hydrogen, and the other R SN is carbobenzyloxy,
• each R SN1 of the sugar substituent ⁇ N(R SN1 ) 2 is independently hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or a nitrogen protecting group, or optionally two R SN1 are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.
• at least one instance of R SN1 is not methyl.
• at least one R SN1 is hydrogen.
• at least one R SN1 is optionally substituted C 1 -C 6 alkyl.
• At least one R SN1 is optionally substituted carbocyclyl. In certain embodiments, at least one R SN1 is optionally substituted aryl. In certain embodiments, at least one R SN1 is optionally substituted heterocyclyl. In certain embodiments, at least one R SN1 is optionally substituted heteroaryl. In certain embodiments, at least one R SN1 is optionally substituted acyl. In certain embodiments, at least one R SN1 is a nitrogen protecting group. In certain embodiments, two R SN1 are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring.
• At least one R SN1 is optionally substituted C 1 -C 6 alkyl. In certain embodiments, at least one R SN1 is substituted C 1 -C 6 alkyl. In certain embodiments, at least one R SN1 is unsubstituted C 1 -C 6 alkyl. In certain embodiments, at least one R SN1 is optionally substituted C 1 -C 3 alkyl. In certain embodiments, at least one R SN1 is unsubstituted C 1 -C 3 alkyl.
• At least one R SN1 is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl. In certain embodiments, at least one R SN1 is selected from the group consisting of ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl. In certain embodiments, one R SN1 is methyl. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-aryl. In certain
• At least one R SN1 is–C 1 -C 3 alkyl-aryl. In certain embodiments, at least one R SN1 is–C 1 -C 3 alkyl-phenyl. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl- carbocyclyl. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-heterocyclyl. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-heteroaryl. In certain embodiments, at least one R SN1 is–C 1 -C 3 alkyl-heteroaryl.
• At least one R SN1 is–C 1 - C 3 alkyl-pyridyl. In certain embodiments, at least one R SN1 is–CH 2 -pyridyl. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-CO 2 H. In certain embodiments, at least one R SN1 is–C 1 -C 3 alkyl-CO 2 H. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-CN. In certain embodiments, at least one R SN1 is aboutC 1 -C 3 alkyl-CN. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-OH.
• At least one R SN1 is–C 1 -C 3 alkyl-OH. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-SO 2 -C 1 -C 3 alkyl. In certain embodiments, at least one R SN1 is–C 1 -C 6 alkyl-SO 2 -C 1 -C 3 alkyl. In certain embodiments, at least one R SN1 is–C 1 -C 3 alkyl-SO 2 -C 1 -C 3 alkyl. In certain embodiments, at least one R SN1 is–C 1 -C 3 alkyl-SO 2 -C 1 -C 3 alkyl. In certain embodimens, at least one R SN1 is selected from the group consisting of:
• At least one R SN1 is optionally substituted heteroaryl. In certain embodiments, at least one R SN1 is optionally substituted 5- to 6-membered heteroaryl. In certain embodiments, at least one R SN1 is optionally substituted 6-membered heteroaryl. In certain embodiments, at least one R SN1 is optionally substituted 6-membered heteroaryl comprising 1 or 2 nitrogen atoms. In certain embodiments, at least one R SN1 is optionally substituted 6-membered heteroaryl comprising 2 nitrogen atoms.
• At least one R SN1 is optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted pyridazinyl. In certain embodiments, at least one R SN1 is optionally substituted pyrazinyl. In certain embodiments, at least one R SN1 is unsubstituted pyrazinyl. In certain embodiments, at least one R SN1 is of the formula:
• two R SN1 are joined to form an optionally substituted heterocyclyl or heteroaryl ring. In certain embodiments, two R SN1 are joined together to form optionally substituted heteroaryl. In certain embodiments, two R SN1 are joined together to form optionally substituted 5-membered heteroaryl. In certain embodiments, two R SN1 are joined together to form an optionally substituted pyrrol ring. In certain embodiments, two R SN1 are joined together to form an optionally substituted imizazole ring. In certain embodiments, two R SN1 are joined together to form an unsubstituted pyrrol ring. In certain embodiments, two R SN1 are joined together to form an unsubstituted imizazole ring.
• two R SN1 are joined together to form optionally substituted heterocyclyl. In certain embodiments, two R SN1 are joined together to form optionally substituted 3- to 6-membered heterocyclyl. In certain embodiments, two R SN1 are joined together to form optionally substituted 5-membered heterocyclyl. In certain embodiments, two R SN1 are joined together to form optionally substituted 6-membered heterocyclyl. In certain embodiments, two R SN1 are joined together to form an optionally substituted pyrrolidine ring. In certain embodiments, two R SN1 are joined together to form an
• two R SN1 are joined together to form a pyrrolidine ring substituted with one instance of–OH.
• two R SN1 are joined together to form a 5-membered heterocyclic ring comprising two heteroatoms selected from O and N.
• two R SN1 are joined together to form an optionally substituted oxazoline ring.
• two R SN1 are joined together to form an oxazoline ring substituted with one instance of–CH 2 OH.
• two R SN1 are joined together to form a 6-membered heterocyclic ring comprising two heteroatoms selected from O and N.
• two R SN1 are joined together to form an optionally substituted morpholino ring. In certain embodiments, two R SN1 are joined together to form an unsubstituted morpholino ring. In certain embodiments, two R SN1 are joined
• R SN1 are joined together to form one of the following: , .
• two R SN1 are joined together to form one of
• At least one of R SN1 is a nitrogen protecting group. In certain embodiments, at least one of R SN1 is tert-butyloxycarbonyl (Boc). In certain embodiments, at least one of R SN1 is benzyl (–CH 2 -phenyl). In certain embodiments, both R SN1 are benzyl. [0097] In certain embodiments, the moiety represented by the formula–N(R SN1 ) 2 is of one
• the moiety represented by the formula–N(R SN1 ) 2 is not:
• the moiety represented by the formula–N(R SN1 ) 2 is not: . In certain embodiments, the moiety represented by the formula–N(R SN1 ) 2 is not: . In certain embodiments, the moiety represented by the formula–N(R SN1 ) 2 is not: Group R SO
• each R SO may independently be hydrogen, optionally substituted C 1 -C 6 alkyl, a carbohydrate, or an oxygen protecting group.
• R SO is hydrogen. In some embodiments, R SO is optionally substituted C 1 -C 6 alkyl. In some embodiments, R SO is C 1 -C 6 alkyl. In some embodiments, R SO is methyl. In some embodiments, R SO is ethyl, propyl, or butyl. In certain embodiments, R SO is an oxygen protecting group. In some embodiments, R SO is alkoxycarbonyl. In some embodiments, R SO is methoxycarbonyl.
• R SO is acetyl, benzoyl, benzyl, methoxymethyl ether, p-methoxybenzyl ether, methylthiomethylether, pivaloyl, tetrahydropyranyl, tetrahydrofuranyl, triphenylmethyl, or silyl (e.g., trimethyl silyl, tert-butyldimethylsilyl, triisopropylsilyloxymethyl, triisopropylsilyl).
• R SO is a carbohydrate.
• R SO is a monosaccharide.
• each of R 1a and R 1b is independently hydrogen, halogen, acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocylyl, optionally substituted aryl, optionally substituted heteroaryl.
• the carbon to which R 1a and R 1b are attached is a stereocenter of the (R)-configuration.
• the carbon to which R 1a and R 1b are attached is a stereocenter of the (S)- configuration.
• At least one of R 1a and R 1b is hydrogen. In certain embodiments, both R 1a and R 1b are hydrogen. In certain embodiments, at least one of R 1a and R 1b is halogen; e.g. ⁇ F, ⁇ Cl, ⁇ Br, or I. In certain embodiments, both R 1a and R 1b are halogen; e.g. ⁇ F, ⁇ Cl, ⁇ Br, or I.
• At least one of R 1a and R 1b is acyl. In certain embodiments, at least one of R 1a and R 1b is a carboxylic acid. In certain embodiments, at least one of R 1a and R 1b is a ketone. In certain embodiments, at least one of R 1a and R 1b is an aldehyde (- CHO).
• At least one instance of R 1a and R 1b is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl optionally substituted C 1-2 alkyl, optionally substituted C 2-3 alkyl, optionally substituted C 3-4 alkyl, optionally substituted C 4- 5 alkyl, or optionally substituted C 5-6 alkyl.
• at least one instance of R 1a and R 1b is ⁇ CH 3 .
• both instances of R 1a and R 1b are ⁇ CH 3 .
• At least one instance of R 1a and R 1b is alkyl substituted with one or more halogen atoms, e.g., optionally substituted haloalkyl; e.g., ⁇ CF 3 , ⁇ CF 2 CF 3 , or ⁇ CF 2 H. In certain embodiments, at least one of R 1a and R 1b is ⁇ CH 2 CHO.
• At least one instance of R 1a and R 1b is optionally substituted alkenyl, e.g., optionally substituted C 2-6 alkenyl, optionally substituted C 2-3 alkenyl, optionally substituted C 3-4 alkenyl, optionally substituted C 4-5 alkenyl, or optionally substituted C 5-6 alkenyl.
• at least one instance of R 1a and R 1b is vinyl, allyl, or prenyl.
• At least one instance of R 1a and R 1b is optionally substituted carbocyclyl, e.g., optionally substituted C 3-6 carbocyclyl, optionally substituted C 3- 4 carbocyclyl, optionally substituted C 4-5 carbocyclyl, or optionally substituted C 5-6 carbocyclyl.
• at least one instance of R 1a and R 1b is optionally substituted heterocylyl, e.g., optionally substituted 3-6 membered heterocyclyl.
• at least one instance of R 1a and R 1b is optionally substituted aryl, e.g., optionally substituted phenyl.
• at least one instance of R 1a and R 1b is optionally substituted heteroaryl, e.g., optionally substituted 5- to 6-membered heteroaryl.
• At least one of R 1a and R 1b is:
• each of R 2a and R 2b is independently hydrogen, halogen, optionally substituted alkyl, or optionally substituted alkenyl.
• the carbon to which R 2a and R 2b are attached is a stereocenter of the (R)- configuration. In certain embodiments, the carbon to which R 2a and R 2b are attached is a stereocenter of the (S)-configuration.
• R 2a and R 2b are hydrogen. In certain embodiments, both R 2a and R 2b are hydrogen. In certain embodiments, at least one of R 2a and R 2b is halogen; e.g. ⁇ F, ⁇ Cl, ⁇ Br, or I. In certain embodiments, both R 2a and R 2b are halogen; e.g. ⁇ F, ⁇ Cl, ⁇ Br, or I.
• At least one instance of R 2a and R 2b is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl optionally substituted C 1-2 alkyl, optionally substituted C 2-3 alkyl, optionally substituted C 3-4 alkyl, optionally substituted C 4- 5 alkyl, or optionally substituted C 5-6 alkyl.
• at least one instance of R 2a and R 2b is ⁇ CH 3 .
• both instances of R 2a and R 2b are ⁇ CH 3 .
• At least one instance of R 2a and R 2b is alkyl optionally substituted with one or more halogen atoms, e.g., optionally substituted haloalkyl; e.g., ⁇ CF 3 , ⁇ CF 2 CF 3 , or ⁇ CF 2 H. In certain embodiments, at least one of R 2a and R 2b is ⁇ CH 2 CHO. Groups R 3 and R 4
• each of R 3 and R 4 hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or ⁇ OR 3a .
• the carbon to which R 3 and R 4 are attached is a stereocenter of the (R)-configuration. In certain embodiments, the carbon to which R 3 and R 4 are attached is a stereocenter of the (S)-configuration.
• At least one of R 3 and R 4 is hydrogen. In certain embodiments, both R 3 and R 4 are hydrogen. In certain embodiments, at least one of R 3 and R 4 is halogen; e.g. ⁇ F, ⁇ Cl, ⁇ Br, or I. In certain embodiments, both R 3 and R 4 are halogen; e.g. ⁇ F, ⁇ Cl, ⁇ Br, or I.
• At least one instance of R 3 and R 4 is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl. In certain embodiments, at least one instance of R 3 and R 4 is ⁇ CH 3 . In certain embodiments, both instances of R 3 and R 4 are ⁇ CH 3 .
• At least one instance of R 3 and R 4 is optionally substituted alkenyl, e.g., optionally substituted C 2-6 alkenyl, optionally substituted C 2-3 alkenyl, optionally substituted C 3-4 alkenyl, optionally substituted C 4-5 alkenyl, or optionally substituted C 5- 6 alkenyl.
• at least one instance of R 3 and R 4 is vinyl, allyl, or prenyl.
• At least one instance of R 3 and R 4 is ⁇ OR 3a . In certain embodiments, at least one instance of R 3 and R 4 is ⁇ OH. In certain embodiments, at least one instance of R 3 and R 4 is ⁇ OMe. In certain embodiments, R 3 is methyl, and R 4 is ⁇ OMe. In certain embodiments, at R 3 is ⁇ OMe, and R 4 is methyl. In certain embodiments, at least one instance of R 3 and R 4 is ⁇ OR 3a . Each instance of R 3a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an oxygen protecting group, or of formula: [00115] In certain embodiments, R 3a is hydrogen.
• R 3a is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl. In certain embodiments, R 3a is ⁇ CH 3 . In certain embodiments, R 3a is optionally substituted alkenyl, e.g., optionally substituted C 2- 6 alkenyl. In certain embodiments, R 3a is vinyl, allyl, or prenyl. In certain embodiments, R 3a is an oxygen protecting group.
• R 3a is of formula:
• Each L C3 is independently a bond, or is a linking group selected from optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted heteroalkenylene, and optionally substituted heteroalkynylene, or combinations thereof.
• L C3 is a bond.
• L C3 is optionally substituted alkylene, e.g., substituted or unsubstituted C 1-6 alkylene.
• L C3 is of the formula ⁇ (CH 2 ) n ⁇ , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• L C3 is substituted or unsubstituted alkenylene, e.g., substituted or unsubstituted C 2-6 alkenylene.
• L C3 is substituted or unsubstituted alkynylene, e.g., substituted or unsubstituted C 2-6 alkynylene.
• Each A 3 is independently optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• a 3 is optionally substituted carbocyclyl, e.g., optionally substituted C 3- 6 carbocyclyl.
• a 3 is optionally substituted heterocyclyl, e.g., optionally substituted 3-6 membered heterocyclyl.
• a 3 is optionally substituted aryl, e.g., optionally substituted monocyclic aryl, optionally substituted 5,6-fused bicyclic aryl, or optionally substituted 6,6-fused aryl.
• a 3 is optionally substituted heteroaryl, e.g., e.g., optionally substituted 5-6 membered heteroaryl, optionally substituted 5,6 fused-bicyclic heteroaryl, or optionally substituted 6,6 fused- bicyclic heteroaryl.
• a 3 is selected from any one of the following aryl or heteroaryl ring systems:
• R 3 is ⁇ OR 3a , wherein ⁇ O R3a is:
• R 4 is ⁇ OR 3a , wherein ⁇ O R3a is: .
• At least one of R 3 and R 4 is: Groups R 5a and R 5b
• each instance of R 5a and R 5b is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl.
• one instance of R 5a and R 5b is hydrogen, and the other of R 5a and R 5b is a non-hydrogen group.
• each instance of R 5a and R 5b is hydrogen.
• each instance of R 5a and R 5b is a non-hydrogen group.
• the carbon to which R 5a and R 5b is attached are a stereocenter of the (R)-configuration. In certain embodiments, the carbon to which R 5a and R 5b are attached is a stereocenter of the (S)-configuration.
• At least one instance of R 5a and R 5b is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl, optionally substituted C 1-2 alkyl, optionally substituted C 2-3 alkyl optionally substituted C 3-4 alkyl, optionally substituted C 4- 5 alkyl, or optionally substituted C 5-6 alkyl.
• at least one instance of R 5a and R 5b is ⁇ CH 3 .
• both instances of R 5a and R 5b are ⁇ CH 3 .
• R 6 and/or R 10 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl.
• R 6 is hydrogen.
• R 10 is hydrogen.
• R 6 is hydrogen and R 10 is hydrogen.
• both of R 6 and R 10 are non-hydrogen groups.
• the carbon to which R 6 and R 10 are attached is a stereocenter of the (R)-configuration. In certain embodiments, the carbon to which R 6 and R 10 are attached is a stereocenter of the (S)-configuration.
• At least one instance of R 6 and R 10 is optionally substituted alkenyl, e.g., optionally substituted C 2-6 alkenyl. In certain embodiments, at least one instance of R 6 and R 10 is optionally substituted alkynyl, e.g., optionally substituted C 2-6 alkynyl.
• At least one instance of R 6 and R 10 is optionally substituted carbocyclyl, e.g., optionally substituted C 3-6 carbocyclyl. In certain embodiments, at least one instance of R 6 and R 10 is optionally substituted heterocyclyl, e.g., optionally substituted 3-6 membered heterocyclyl. In certain embodiments, at least one instance of R 6 and R 10 is optionally substituted aryl; e.g., optionally substituted phenyl. In certain embodiments, at least one instance of R 6 and R 10 is optionally substituted aralkyl, e.g., optionally substituted benzyl.
• At least one instance of R 6 and R 10 is optionally substituted heteroaryl, e.g., optionally substituted 5- to 6-membered heteroaryl.
• at least one instance of R 6 and R 10 is optionally substituted heteroaralkyl; e.g., optionally substituted pyrazolylalkyl, imidazolylalkyl, thiazolylalkyl, oxazolylalkyl, pyridinylalkyl, pyrimidinylalkyl, or pyrazinylalkyl.
• R 6 and R 10 are halogen, e.g., fluoro, bromo, chloro, or iodo.
• R 6 is fluoro.
• R 10 is fluoro.
• R 6 is fluoro, and R 10 is methyl.
• R 6 is methyl, and R 10 is fluoro.
• R 6 is:
• R 10 is hydrogen or fluoro.
• Group R 7
• R 7 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R 7 is hydrogen.
• R 7 is a non-hydrogen group, and the carbon to which R 7 is attached is a stereocenter of the (R)-configuration.
• R 7 is a non-hydrogen group, and the carbon to which R 7 is attached is a stereocenter of the (S)-configuration.
• R 7 is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl optionally substituted C 1-2 alkyl, optionally substituted C 2-3 alkyl, optionally substituted C 3-4 alkyl, optionally substituted C 4-5 alkyl, or optionally substituted C 5- 6 alkyl.
• R 7 is ⁇ CH 3 or ⁇ CH 2 CH 3 .
• Group R 8
• R 8 is hydrogen, halogen, or optionally substituted C 1 - C 6 alkyl. In certain embodiments, R 8 is hydrogen. In certain embodiments, R 8 is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl, optionally substituted C 1-2 alkyl, optionally substituted C 2-3 alkyl, optionally substituted C 3-4 alkyl, optionally substituted C 4- 5 alkyl, or optionally substituted C 5-6 alkyl. In certain embodiments, R 8 is ⁇ CH 3 or ⁇ CH 2 CH 3 . In certain embodiments, R 8 is halogen, e.g., fluoro, bromo, chloro, or iodo. Group R 14
• R 14 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group, or of formula:
• Groups of formula (L C1 -ii) are, in certain embodiments, a precursor to groups of (L C1 -iii). Transformations of group 14 have been described in detail in PCT publication WO2014/165792, which is incorporated herein in its entirety by reference. The present invention includes all possible embodiments of R 14 , L C1 , L C2 , A, A 1 , and R 23 described in WO2014/165792.
• R 14 is hydrogen.
• R 14 is optionally substituted alkyl, e.g., optionally substituted C 1-6 alkyl optionally substituted C 1-2 alkyl, optionally substituted C 2-3 alkyl, optionally substituted C 3-4 alkyl, optionally substituted C 4- 5 alkyl, or optionally substituted C 5-6 alkyl.
• R 14 is ⁇ CH 3 or ⁇ CH 2 CH 3 .
• R 14 is optionally substituted alkenyl, e.g., optionally substituted C 2-6 alkenyl, optionally substituted C 2-3 alkenyl, optionally substituted C 3-4 alkenyl, optionally substituted C 4-5 alkenyl, or optionally substituted C 5-6 alkenyl.
• optionally substituted alkenyl e.g., optionally substituted C 2-6 alkenyl, optionally substituted C 2-3 alkenyl, optionally substituted C 3-4 alkenyl, optionally substituted C 4-5 alkenyl, or optionally substituted C 5-6 alkenyl.
• R 14 is vinyl, allyl, or prenyl.
• R 14 is optionally substituted alkynyl, e.g., optionally substituted C 2-6 alkynyl, optionally substituted C 2- 3 alkynyl, optionally substituted C 3-4 alkynyl, optionally substituted C 4-5 alkynyl, or optionally substituted C 5-6 alkynyl.
• R 14 is optionally substituted carbocyclyl, e.g., optionally substituted C 3-6 carbocyclyl, optionally substituted C 3-4 carbocyclyl, optionally substituted C 4-5 carbocyclyl, or optionally substituted C 5-6 carbocyclyl.
• R 14 is optionally substituted heterocyclyl, e.g., optionally substituted 3-6 membered heterocyclyl.
• R 14 is optionally substituted aryl; e.g., optionally substituted phenyl.
• R 14 is optionally substituted heteroaryl, e.g., optionally substituted 5- to 6-membered heteroaryl.
• A is optionally substituted heteroaryl, e.g., 5- to 6- membered optionally substituted heteroaryl.
• R 14 is of the formula (L C1 -viii):
• each instance of Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 is independently CR Y , O, S, N, or NR Y , wherein R Y is hydrogen or optionally substituted alkyl.
• R 14 is of formula:
• each instance of L C1 and L C2 is independently a bond, or a linking group selected from the group consisting of optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene; optionally substituted heteroalkylene, optionally substituted heteroalkenylene, optionally substituted
• heteroalkynylene and combinations thereof.
• L C1 is a bond. It is generally understood that if L C1 is a bond, then the group ⁇ LG, ⁇ A 1 , or ⁇ A ⁇ L C2 ⁇ R 23 , as described herein, is directly attached to the parent moiety, e.g., the macrolide or intermediate compounds. Furthermore, in certain embodiments, L C2 is a bond. It is generally understood that if L C2 is a bond, then the group R 23 is directly attached to A, as described herein.
• L C1 and L C2 are each optionally and independently linking groups comprising at least one instance of optionally substituted alkylene, e.g., substituted or unsubstituted C 1-6 alkylene.
• L C1 and L C2 are each optionally and independently an alkylene linking group of the formula ⁇ (CH 2 ) n ⁇ , wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• L C1 and L C2 are each optionally and independently linking groups comprising at least one instance of substituted or unsubstituted alkenylene, e.g., substituted or unsubstituted C 2-6 alkenylene.
• L C1 and L C2 are each optionally and independently linking groups comprising at least one instance of substituted or unsubstituted alkynylene, e.g., substituted or unsubstituted C 2-6 alkynylene.
• L C1 is:
• each of k1 and k2 are independently 0, 1, 2, 3, or 4.
• L C1 is: .
• R 23 is: .
• each R 23 is independently optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R 23 is optionally substituted carbocyclyl, e.g., optionally substituted C 3-6 carbocyclyl.
• R 23 is optionally substituted heterocyclyl, e.g., optionally substituted 3-6 membered heterocyclyl.
• R 23 is optionally substituted aryl, e.g., optionally substituted monocyclic aryl, optionally substituted 5,6-fused bicyclic aryl, or optionally substituted 6,6-fused aryl.
• R 23 is optionally substituted phenyl. In certain embodiments, R 23 is optionally substituted napthyl. In certain embodiments, R 23 is optionally substituted heteroaryl, e.g., optionally substituted monocyclic heteoaryl or optionally substituted bicyclic heteroaryl, e.g., optionally substituted 5-6 membered heteroaryl, optionally substituted 5,6 fused-bicyclic heteroaryl, or optionally substituted 6,6 fused-bicyclic heteroaryl. In certain embodiments, R 23 is amino substituted aryl, e.g., aminophenyl, or amino substituted heteroaryl, e.g., aminothiazole, or aminodithiazole.
• R 23 is selected from any one of the following aryl or heteroaryl ring systems:
• R 23 is:
• R 14 is of formula (L C1 -v): ,
• R 23 is: , or
• R 14 is of formula (L C1 -ii):
• a 1 is ⁇ N 3 and L C1 is of formula: Exemplary macrolides and sugars
• Compounds of Formula (I) comprise a macrolide unit and a sugar unit.
• the macrolide unit may be described as fragment (A), and the sugar unit as fragment (B), as depicted below.
• the point of attachment between unit (A) and unit (B) is indicated with“B” in unit (A), and“A” in unit (B), i.e., the sugar unit is attached to the C5 position of the macrolide by a single carbon-oxygen bond.
• Compounds of Formula (I-N) also comprise a macrolide unit and a sugar unit; the macrolide unit may be described as fragment (A), and the sugar unit as fragment (B-N), as depicted below.
• the point of attachment between unit (A) and unit (B-N) is indicated with “B” in unit (A), and“A” in unit (B-N), i.e., the sugar unit is attached to the C5 position of the macrolide by a single carbon-oxygen bond.
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B) is of formula:
• the sugar unit (B-N) is of formula:
• the sugar unit (B-N) is of formula: .
• the sugar unit (B-N) is of formula:
• the sugar unit (B-N) is of formula:
• the sugar unit (B-N) is of formula:
• the sugar unit (B-N) is of formula:
• the sugar unit (B-N) is of formula:
• Exemplary fragment units for macrolide unit (A) and sugar unit (B) are depicted in Tables 1A and 1B, respectively. Exemplary fragment units for macrolide unit (B-N) are depicted in Table 1B-N.
• the compound of Formula (I) comprises a macrolide unit (A) selected from Table 1A.
• the compound of Formula (I) comprises a sugar unit (B) selected from Table 1B.
• the compound of Formula (I) comprises a macrolide unit selected from Table 1A, and sugar unit selected from Table 1B.
• the compound of Formula (I-N) comprises a macrolide unit (A) selected from Table 1A.
• the compound of Formula (I-N) comprises a sugar unit (B-N) selected from Table 1B-N.
• the compound of Formula (I-N) comprises a macrolide unit selected from Table 1A, and sugar unit selected from Table 1B-N.
• the invention contemplates all possible combinations of macrolide and sugar units listed in Tables 1A and 1B, but neither the macrolide unit nor sugar unit is in any way limited to those listed in Tables 1A and 1B.
• the invention also contemplates all possible combinations of macrolide and sugar units listed in Tables 1A and 1B-N, but neither the macrolide unit nor sugar unit is in any way limited to those listed in Tables 1A and 1B-N.
• the macrolide is a compound listed in Table E1. In other specific embodiments, the macrolide is a compound listed in Table E1-N.
• Table 1A Examples of macrolide unit (A).
• the sugar unit represented by (B-N) is not of the formula:
• the sugar unit represented by (B-N) is not
• the sugar unit represented by (B-N) is not of the formula: In certain embodiments, the sugar moiety
• the sugar moiety of a compound of Formula (I-N) is not of the formula: . In certain embodiments, the sugar moiety of a compound of Formula (I-N) is not of the formula: . In certain embodiments, the sugar moiety of a compound of Formula (I-N) is not of the formula: . In certain embodiments, the sugar moiety of a compound of Formula
• the present invention provides a macrolide eastern half intermediate of Formula (E):
• R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R A , R B , R S4a , R S4b , R S6a , R S6b , R SN , R SO , and R Z2 are as described herein;
• p′ is 0, 1, or 2;
• q is 0 or 1
• LG is a leaving group
• Z 4 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ NR Z2 ⁇ ;
• R Z3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocylyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each of R P1 , R P2 , and R P3 is independently optionally substituted alkyl, optionally
• substituted alkenyl optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• G 4 is of formula:
• each instance of X G2 is ⁇ OR 15 , ⁇ SR 15 , or ⁇ N(R 15 ) 2 ;
• each instance of R 15 is independently silyl, optionally substituted alkyl, optionally
• each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• the present invention provides an uncyclized macrolide intermediate of Formula (N):
• Z, p, R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 14 , R A , R B , R S4a , R S4b , R S6a , R S6b , R SN , R SO , and R Z2 are as described herein;
• P 1 is hydrogen, silyl, optionally substituted alkyl, or optionally substituted alkenyl,
• optionally substituted alkynyl optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen, nitrogen, or thiol protecting group;
• G 3 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ N(R G1 ) ⁇ , wherein R G1 is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
• G 4 is of formula:
• each instance of X G2 is ⁇ OR 15 , ⁇ SR 15 , or ⁇ N(R 15 ) 2 ;
• each instance of R 15 is independently silyl, optionally substituted alkyl, optionally
• each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• the present invention provides an uncyclized ketolide intermediate of Formula (M-2):
• R 1a , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 14 , R A , R B , R S4a , R S4b , R S6a , R S6b , R SN , and R SO are as described herein;
• R 11 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group;
• P 1 is hydrogen, silyl, optionally substituted alkyl, or optionally substituted alkenyl,
• optionally substituted alkynyl optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen, nitrogen, or thiol protecting group;
• G 3 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ N(R G1 ) ⁇ , wherein R G1 is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
• G 4 is of formula:
• each instance of X G2 is ⁇ OR 15 , ⁇ SR 15 , or ⁇ N(R 15 ) 2 ;
• each instance of R 15 is independently silyl, optionally substituted alkyl, optionally
• each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• E-N a macrolide eastern half intermediate of Formula (E-N):
• R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R B , R S4a , R S4b , R S5a , R S5b , R SN1 , R SO , and R Z2 are as
• p′ is 0, 1, or 2;
• q is 0 or 1
• LG is a leaving group
• Z 4 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ NR Z2 ⁇ ;
• R Z3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocylyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each of R P1 , R P2 , and R P3 is independently optionally substituted alkyl, optionally
• substituted alkenyl optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• G 4 is of formula:
• each instance of X G2 is ⁇ OR 15 , ⁇ SR 15 , or ⁇ N(R 15 ) 2 ; each instance of R 15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R 15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and
• each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• the present invention provides an uncyclized macrolide intermediate of Formula (N-N):
• R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 14 , R A , R B , R S4a , R S4b , R S5a , R S5b , R SN1 , R SO , and R Z2 are as described herein;
• P 1 is hydrogen, silyl, optionally substituted alkyl, or optionally substituted alkenyl,
• optionally substituted alkynyl optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen, nitrogen, or thiol protecting group;
• G 3 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ N(R G1 ) ⁇ , wherein R G1 is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
• G 4 is of formula:
• each instance of X G2 is ⁇ OR 15 , ⁇ SR 15 , or ⁇ N(R 15 ) 2 ; each instance of R 15 is independently silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R 15 groups are joined to form an optionally substituted heterocyclyl or heteroaryl ring; and
• each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• the present invention provides an uncyclized ketolide intermediate of Formula (M-2-N):
• R 1a , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 14 , R A , R B , R S4a , R S4b , R S5a , R S5b , R SN1 , and R SO are as described herein;
• R 11 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group;
• P 1 is hydrogen, silyl, optionally substituted alkyl, or optionally substituted alkenyl,
• optionally substituted alkynyl optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen, nitrogen, or thiol protecting group;
• G 3 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ N(R G1 ) ⁇ , wherein R G1 is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
• G 4 is of formula:
• each instance of X G2 is ⁇ OR 15 , ⁇ SR 15 , or ⁇ N(R 15 ) 2 ;
• each instance of R 15 is independently silyl, optionally substituted alkyl, optionally
• each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• macrolides of the present invention are prepared by coupling an eastern half of Formula (E) and a western half of Formula (W) to provide an uncyclized macrolide precursor of Formula (N) as depicted in Scheme 1, and the precursor of Formula (N) is cyclized to give a macrolide of Formula (I) as depicted in Scheme 2.
• macrolides of the present invention are prepared by coupling an eastern half of Formula (E-N) and a western half of Formula (W) to provide an uncyclized macrolide precursor of Formula (N-N) as depicted in Scheme 1-N, and the precursor of Formula (N-N) is cyclized to give a macrolide of Formula (I-N) as depicted in Scheme 2-N.
• Z, p, R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 10 , R 14 , R A , R B , R S4a , R S4b , R S6a , R S6b , R S5a , R S5b , R SN , R SN1 , R SO , and R Z2 are as defined herein for a compound of Formula (I) or Formula (I-N), unless otherwise stated.
• q is 0 or 1
• t is 0 or 1;
• LG is a leaving group
• Z 4 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ NR Z2 ⁇ ;
• R Z3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocylyl, optionally substituted aryl, or optionally substituted
• each of R P1 , R P2 , and R P3 is independently optionally substituted alkyl, optionally
• substituted alkenyl optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• P 1 is hydrogen, silyl, optionally substituted alkyl, or optionally substituted alkenyl,
• optionally substituted alkynyl optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen, nitrogen, or thiol protecting group;
• G 3 is ⁇ O ⁇ , ⁇ S ⁇ , or ⁇ N(R G1 ) ⁇ , wherein R G1 is hydrogen, optionally substituted alkyl, or a nitrogen protecting group;
• G 4 is of formula: ;
• each instance of X G2 is ⁇ OR 15 , ⁇ SR 15 , or ⁇ N(R 15 ) 2 ;
• each instance of R 15 is independently silyl, optionally substituted alkyl, optionally
• each instance of R 16a is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• p′ is 0, 1, or 2;
• q is 0 or 1
• t is 0 or 1;
• LG is a leaving group
• R Z3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• p′ is 0, 1, or 2;
• q is 0 or 1
• t is 0 or 1;
• LG is a leaving group
• R Z3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• nucleophilic substitution optionally in the presence of a base, provides an uncyclized macrolide precursor of formula (N), wherein Z is ⁇ NR Z2 ⁇ , and wherein R Z2 is a hydrogen or non-hydrogen group.
• exemplary bases include, but are not limited to, organic bases (e.g., pyridine, DMAP, Hunig’s base) and inorganic bases (e.g., sodium bicarbonate, sodium carbonate).
• Exemplary leaving groups include bromine, chlorine, iodine, tosylate, triflate, mesylate, and besylate.
• Scheme 4-N Analogous routes to uncyclized macrolide precursors of Formula (N- N), wherein Z is ⁇ NR Z2 ⁇ , and wherein R Z2 is a hydrogen or non-hydrogen group.
• Exemplary reductive amination conditions include, but are not limited to, use of B 10 H 14 , InCl 3 /Et 3 SiH, NaBH 4 , NaBH 4 /H 3 BO 3 , NaBH 3 CN or NaBH(OAc) 3 , optionally in the prescence of an acid (e.g., AcOH, TFA) or protic solvent (e.g., MeOH).
• R Z2 is hydrogen.
• R Z2 is methyl.
• R Z2 is a nitrogen protecting group.
• Analagous routes to uncyclized macrolide precursors of Formula (N-N), wherein Z is ⁇ NR Z2 ⁇ , and wherein R Z2 is hydrogen or a non-hydrogen group are shown in Scheme 5-N. Scheme 6a.
• nitro-aldol reaction (Henry reaction) coupling products, and oxidized, reduced, and/or addition products formed therefrom.
• the nitro aldol reaction may be catalyzed or promoted by many different sets of conditions, e.g., use of an organic base, inorganic base, quaternary ammonium salt, and/or a catalyst; and use of protic or aprotic solvents and/or use of solventless conditions. See, e.g., Luzzio Tetrahedron (2001) 915-945, for a review of various conditions employed in a nitro aldol reaction. Scheme 7a.
• R 11 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group;
• R Z3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each of R P1 , R P2 , and R P3 is independently optionally substituted alkyl, optionally
• substituted alkenyl optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• the coupling of the eastern and western halves is as depicted in Scheme 8-N, Scheme 8-N.
• R 11 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group;
• R Z3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each of R P1 , R P2 , and R P3 is independently optionally substituted alkyl, optionally
• substituted alkenyl optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• LG is a leaving group as defined herein (e.g., chloro)
• substituted hydroxyl e.g., to provide a carbonate ester
• substituted thiol substituted amino
• R 11 is hydrogen
• the isocyanate reacts with the free hydroxyl group and ⁇ NHR 14 undergoes the conjugate addition reaction in a single step.
• the intermediate acyclic carbamate is isolated.
• base is added to the isolated acyclic carbamate to promote the conjugate addition reaction.
• R 6 is a hydrogen or non-hydrogen group, macrocyclization of the compound of Formula (N), e.g., wherein P 1 is hydrogen, provides a macrolide with one hydrogen substiuent at C2.
• Enolization of the macrolide, followed by addition of a non-hydrogen group R 10 e.g., with a base and an R 10 alkylating agent, e.g., R 10 ⁇ LG, or with a halogenating agent if R 10 is halogen
• R 10 e.g., with a base and an R 10 alkylating agent, e.g., R 10 ⁇ LG, or with a halogenating agent if R 10 is halogen
• R 6 is a hydrogen or non-hydrogen group, macrocyclization of the compound of Formula (N-N), e.g., wherein P 1 is hydrogen, provides a macrolide with one hydrogen substiuent at C2.
• Enolization of the macrolide, followed by addition of a non-hydrogen group R 10 e.g., with a base and an R 10 alkylating agent, e.g., R 10 ⁇ LG, or with a halogenating agent if R 10 is halogen
• R 10 e.g., with a base and an R 10 alkylating agent, e.g., R 10 ⁇ LG, or with a halogenating agent if R 10 is halogen
• each of R 6 and R 10 is a hydrogen or non-hydrogen group, macrocyclization of the compound of Formula (N) e.g., wherein P 1 is hydrogen, provides a macrolide of Formula (I).
• the modified sugar is typically attached to the macrolide framework during synthesis of the eastern half, but may also be attached at other stages of the preparation.
• the sugar may be attached by a glycosylation reaction between the hydroxyl group at the C5 position and a suitable glycosyl donor as exemplified in Scheme 14.
• Typical glycosyl donors have a leaving group attached to the anomeric carbon.
• Exemplary groups for the anomeric leaving group include halogens, thioethers, acetimidates, acetate, phosphates, and O- pentenyl.
• a thioglycoside is sugar with a thioether group at the anomeric carbon of the sugar.
• the modified sugar moiety is attached to the macrolide framework as a thioglycoside.
• substituents of the sugar may be modified after glycosylation of the macrolide or macrolide precursor (e.g., eastern half).
• the sugar is not further modified after glycosylation of the macrolide or macrolide precursor.
• the present invention provides pharmaceutical compositions comprising a macrolide as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
• compositions agents include any and all solvents, diluents, or other liquid vehicles, dispersions, suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
• solvents diluents, or other liquid vehicles, dispersions, suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like.
• compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include the steps of bringing the macrolide of the present invention into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
• compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
• a“unit dose” is discrete amount of the pharmaceutical composition comprising a predetermined amount of the macrolide of the present invention.
• the amount of the macrolide is generally equal to the dosage of the macrolide which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
• Relative amounts of the macrolide, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
• the composition may comprise between 0.1% and 100% (w/w) macrolide.
• compositions include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils.
• Excipients such as cocoa butter and suppository waxes, coloring agents, coating agents, sweetening, flavoring, and perfuming agents may also be present in the composition.
• Liquid dosage forms for oral and parenteral administration include
• the liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents, and emulsifiers, and mixtures thereof.
• inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents, and emulsifiers, and mixtures thereof.
• the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
• the conjugates of the invention are mixed with solubilizing agents, and mixtures thereof.
• Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation can be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
• acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U.S.P. and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
• the macrolide is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and
• Dosage forms for topical and/or transdermal administration of a macrolide of this invention may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches.
• the macrolide is admixed under sterile conditions with a pharmaceutically acceptable carrier and/or any needed preservatives and/or buffers as can be required.
• compositions are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical
• compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
• Macrolides provided herein are typically formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily amount of the macrolide will be decided by the attending physician within the scope of sound medical judgment.
• the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disease, disorder, or condition being treated and the severity of the disorder; the activity of the specific macrolide employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific macrolide employed; the duration of the treatment; drugs used in combination or coincidental with the specific macrolide employed; and like factors well known in the medical arts.
• the macrolides and compositions provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol.
• enteral e.g., oral
• parenteral intravenous, intramuscular, intra-arterial, intramedullary
• intrathecal subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal
• topical as by powders, ointments, creams, and/or drops
• Oral administration is the preferred mode of administration.
• the subject may not be in a condition to tolerate oral administration, and thus intravenous, intramuscular, and/or rectal administration are also preferred altermative modes of adminsitration.
• an effective amount may be included in a single dose (e.g., single oral dose) or multiple doses (e.g., multiple oral doses).
• any two doses of the multiple doses include different or substantially the same amounts of a compound described herein.
• the frequency of administering the multiple doses to the subject or applying the multiple doses to the tissue or cell is three doses a day, two doses a day, one dose a day, one dose every other day, one dose every third day, one dose every week, one dose every two weeks, one dose every three weeks, or one dose every four weeks.
• a dose (e.g., a single dose, or any dose of multiple doses) described herein includes
• a macrolide or composition can be administered in combination with one or more additional therapeutically active agents.
• the macrolide or composition can be administered concurrently with, prior to, or subsequent to, one or more additional therapeutically active agents.
• each agent will be administered at a dose and/or on a time schedule determined for that agent.
• the additional therapeutically active agent utilized in this combination can be administered together in a single composition or administered separately in different compositions.
• the particular combination to employ in a regimen will take into account compatibility of the inventive macrolide with the additional therapeutically active agent and/or the desired therapeutic effect to be achieved.
• it is expected that additional therapeutically active agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
• Exemplary additional therapeutically active agents include, but are not limited to, antibiotics, anti-viral agents, anesthetics, anti-coagulants, inhibitors of an enzyme, steroidal agents, steroidal or non-steroidal anti-inflammatory agents, antihistamine,
• immunosuppressant agents antigens, vaccines, antibodies, decongestant, sedatives, opioids, pain-relieving agents, analgesics, anti-pyretics, hormones, and prostaglandins.
• Therapeutically active agents include small organic molecules such as drug compounds (e.g., compounds approved by the US Food and Drug Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, and the like.
• drug compounds e.g., compounds approved by the US Food and Drug Administration as provided in the Code of Federal Regulations (CFR)
• peptides e.g., proteins, carbohydrates, monosaccharides
• oligosaccharides polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells.
• the additional therapeutically agent is an antibiotic.
• antibiotics include, but are not limited to, penicillins (e.g., penicillin, amoxicillin), cephalosporins (e.g., cephalexin), macrolides (e.g., erythromycin, clarithormycin,
• tetracyclines e.g., tetracycline, chlortetracycline, oxytetracycline, demeclocycline, methacycline, sancycline, doxycline, aureomycin, terramycin, minocycline, 6-deoxytetracycline, lymecycline, meclocycline, methacycline, rolitetracycline, and glycylcycline antibiotics (e.g., tigecycline)),
• fluoroquinolones e.g., ciprofloxacin, levofloxacin, ofloxacin
• sulfonamides e.g., co-trimoxazole, trimethoprim
• tetracyclines e.g., tetracycline, chlortetracycline, oxytetracycline, demeclocycline, methacycline, sancycline, doxycline, aure
• aminoglycosides e.g., gentamicin, tobramycin, paromomycin
• aminocyclitol e.g., spectinomycin
• chloramphenicol e.g., tobramycin, paromomycin
• quinupristin/dalfoprisin SyndercidTM
• kits e.g., pharmaceutical packs
• the kits provided may comprise an inventive pharmaceutical composition or macrolide and a container (e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container).
• a container e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container.
• provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive pharmaceutical composition or macrolide.
• the inventive composition or macrolide e.g., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container.
• provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive pharmaceutical composition or macrolide.
• the inventive composition or macrolide e.g., a vial, ampule, bottle, syringe, and/
• compositions or macrolide provided in the container and the second container are combined to form one unit dosage form.
• the present invention contemplates using macrolides of the present invention for the treatment of infectious diseases, for example, fungal, bacterial, viral, or parasitic infections, and for the treatment of inflammatory conditions.
• Ketolides are known to exhibit anti-bacterial activity as well as anti-parasitic activity. See, for example, Clark et al.,
• Ketolides are also known to exhibit an anti-inflammatory effect. See, for example, Amsden, Journal of Antimicrobial Chemotherapy (2005) 55:10-21 (chronic pulmonary inflammatory syndromes).
• a method of treating a infectious disease comprising administering an effective amount of a macrolide of the present invention, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
• Such a method can be conducted in vivo (i.e., by administration to a subject) or in vitro (e.g., upon contact with the pathogen, tissue, or cell culture). Treating, as used herein, encompasses therapeutic treatment and prophylactic treatment.
• the effective amount is a therapeutically effective amount.
• the method slows the progress of an infectious disease in the subject.
• the method improves the condition of the subject suffering from an infectious disease.
• the subject has a suspected or confirmed infectious disease.
• the effective amount is a prophylatically effective amount.
• the method prevents or reduces the likelihood of an infectious disease, e.g., in certain embodiments, the method comprises administering a macrolide of the present invention to a subject in need thereof in an amount sufficient to prevent or reduce the likelihood of an infectious disease.
• the subject is at risk of an infectious disease (e.g., has been exposed to another subject who has a suspected or confirmed infectious disease or has been exposed or thought to be exposed to a pathogen).
• an in vitro method of inhibiting pathogenic growth comprising contacting an effective amount of the macrolide of the present invention with a pathogen (e.g., a bacteria, virus, fungus, or parasite) in a cell culture.
• a pathogen e.g., a bacteria, virus, fungus, or parasite
• the infectious disease is caused by a pathogen resistant to other treatments.
• the infectious disease is caused by a pathogen that is multi-drug tolerant or resistant, e.g., the infectious disease is caused by a pathogen that neither grows nor dies in the presence of or as a result of other treatments.
• the infectious disease is a bacterial infection.
• a method of treating a bacterial infection comprising administering an effective amount of a macrolide of the present invention, or a
• the macrolide has a mean inhibitory concentration (MIC), with respect to a particular bacteria, of less than 50 ⁇ g/mL, less than 25 ⁇ g/mL, less than 20 ⁇ g/mL, less than 10 ⁇ g/mL, less than 5 ⁇ g/mL, or less than 1 ⁇ g/mL.
• MIC mean inhibitory concentration
• the bacteria is susceptible (e.g., responds to) or resistant to known commercial macrolides, such as azithromycin, clindamycin, telithromycin, erythromycin, spiramycin, and the like.
• the bactera is resistant to a known macrolide.
• the bacteria is erythromycin resistant (ER).
• the bacterial infection is resistant to other antibiotics (e.g., non-macrolide) therapy.
• the pathogen is vancomycin resistant (VR).
• the pathogen is a methicillin-resistant (MR), e.g., in certain embodiments, the bacterial infection is an methicillin-resistant S. aureus infection (a MRSA infection).
• the bacteria has an efflux (e.g., mef, msr) genotype. In certain embodiments, the bacteria has a methylase (e.g., erm) genotype. In certain embodiments, the bacteria has an efflux (e.g., mef, msr) genotype. In certain embodiments, the bacteria has a methylase (e.g., erm) genotype. In certain
• the bacteria has a constitutive genotype. In certain embodiments, the bacteria has an inducible genotype.
• Exemplary bacterial infections include, but are not limited to, infections with a Gram positive bacteria (e.g., of the phylum Actinobacteria, phylum Firmicutes, or phylum Tenericutes); Gram negative bacteria (e.g., of the phylum Aquificae, phylum Deinococcus- Thermus, phylum Fibrobacteres/Chlorobi/Bacteroidetes (FCB), phylum Fusobacteria, phylum Gemmatimonadest, phylum Ntrospirae, phylum
• a Gram positive bacteria e.g., of the phylum Actinobacteria, phylum Firmicutes, or phylum Tenericutes
• Gram negative bacteria e.g., of the phylum Aquificae, phylum Deinococcus- Thermus, phylum Fibrobacteres/Chlorobi/Bacteroidetes (FCB), phylum Fusobacteria
• Planctomycetes/Verrucomicrobia/Chlamydiae PVC
• phylum Proteobacteria phylum Spirochaetes
• phylum Synergistetes e.g., of the phylum Acidobacteria, phylum Chlroflexi, phylum Chrystiogenetes, phylum Cyanobacteria, phylum Deferrubacteres, phylum Dictyoglomi, phylum Thermodesulfobacteria, or phylum
• the bacterial infection is an infection with a Gram positive bacteria.
• the Gram positive bacteria is a bacteria of the phylum Firmicutes.
• the bacteria is a member of the phylum Firmicutes and the genus Enterococcus, i.e., the bacterial infection is an Enterococcus infection.
• Exemplary Enterococci bacteria include, but are not limited to, E. avium, E. durans, E. faecalis, E.
• the bacteria is a member of the phylum Firmicutes and the genus Staphylococcus, i.e., the bacterial infection is a Staphylococcus infection.
• Exemplary Staphylococci bacteria include, but are not limited to, S. arlettae, S. aureus, S. auricularis, S. capitis, S. caprae, S. carnous, S. chromogenes, S. cohii, S. condimenti, S. croceolyticus, S. delphini, S. devriesei, S. epidermis, S. equorum, S. felis, S. fluroettii, S. gallinarum, S.
• the Staphylococcus infection is an S. aureus infection.
• the S. aureus has an efflux (e.g., mef, msr) genotype.
• the S. aureus has a methylase (e.g., erm) genotype.
• the bacteria is a member of the phylum Firmicutes and the genus Bacillus, i.e., the bacterial infection is a Bacillus infection.
• Bacillus bacteria include, but are not limited to, B. alcalophilus, B. alvei, B. aminovorans, B.
• amyloliquefaciens B. aneurinolyticus, B. anthracis, B. aquaemaris, B. atrophaeus, B.
• boroniphilus B. brevis, B. caldolyticus, B. centrosporus, B. cereus, B. circulans, B.
• coagulans B. firmus, B. flavothermus, B. fusiformis, B. globigii, B. infernus, B. larvae, B. laterosporus, B. lentus, B. licheniformis, B. megaterium, B. mesentericus, B. mucilaginosus, B. mycoides, B. natto, B. pantothenticus, B. polymyxa, B. pseudoanthracis, B. pumilus, B. schlegelii, B. sphaericus, B. sporothermodurans, B. stearothermophilus, B. subtilis, B.
• thermoglucosidasius B. thuringiensis, B. vulgatis, and B. weihenstephanensis.
• Bacillus infection is a B. subtilis infection.
• the B. subtilis has an efflux (e.g., mef, msr) genotype.
• the B. subtilis has a methylase (e.g., erm) genotype.
• the bacteria is a member of the phylum Firmicutes and the genus Strepococcus, i.e., the bacterial infection is a Strepococcus infection.
• Exemplary Strepococcus bacteria include, but are not limited to, S. agalactiae, S. anginosus, S. bovis, S. canis, S. constellatus, S. dysgalactiae, S. equinus, S. iniae, S. intermedius, S. mitis, S. mutans, S. oralis, S. parasanguinis, S. peroris, S. pneumoniae, S. pyogenes, S. ratti, S.
• the Strepococcus infection is an S. pyogenes infection.
• the Strepococcus infection is an S. pneumoniae infection.
• the S. pneumoniae has an efflux (e.g., mef, msr) genotype.
• the S. pneumoniae has a methylase (e.g., erm) genotype.
• the bacterial infection is an infection with a Gram negative bacteria.
• the Gram negative bacteria is a bacteria of the phylum Proteobacteria and the genus Escherichia. i.e., the bacterial infection is an Escherichia infection.
• Exemplary Escherichia bacteria include, but are not limited to, E. albertii, E.
• the Escherichia infection is an E. coli infection.
• the Gram negative bacteria is a bacteria of the phylum Proteobacteria and the genus Haemophilus. i.e., the bacterial infection is an Haemophilus infection.
• Exemplary Haemophilus bacteria include, but are not limited to, H. aegyptius, H. aphrophilus, H. avium, H. ducreyi, H. felis, H. haemolyticus, H. influenzae, H.
• the Escherichia infection is an H. influenzae infection.
• the bacteria is an atypical bacteria, i.e., are neither Gram positive nor Gram negative.
• the infectious disease is an infection with a parasitic infection.
• a method of treating a parasitic infection comprising administering an effective amount of a macrolide of the present invention, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
• the macrolide has a IC 50 (uM) with respect to a particular parasite, of less than 50 uM, less than 25 uM, less than 20 uM, less than 10 uM, less than 5 uM, or less than 1 uM.
• Exemplary parasites include, but are not limited to, Trypanosoma spp. (e.g., Trypanosoma cruzi, Trypansosoma brucei), Leishmania spp., Giardia spp., Trichomonas spp., Entamoeba spp., Naegleria spp., Acanthamoeba spp., Schistosoma spp., Plasmodium spp. (e.g., P.
• Trypanosoma spp. e.g., Trypanosoma cruzi, Trypansosoma brucei
• Leishmania spp. Giardia spp.
• Trichomonas spp. Trichomonas spp.
• Entamoeba spp. Entamoeba spp.
• Naegleria spp. Naegleria spp.
• Crytosporidium spp. Crytosporidium spp., Isospora spp., Balantidium spp., Loa Loa, Ascaris lumbricoides, Dirofilaria immitis, and Toxoplasma ssp. (e.g. T. gondii).
• the present invention further a method of treating an inflammatory condition comprising administering an effective amount of a macrolide of the present invention, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
• a method can be conducted in vivo (i.e., by administration to a subject) or in vitro (e.g., upon contact with the pathogen, tissue, or cell culture). Treating, as used herein, encompasses therapeutic treatment and prophylactic treatment.
• the effective amount is a therapeutically effective amount.
• the method slows the progress of an inflammatory condition in the subject.
• the method improves the condition of the subject suffering from an inflammatory condition.
• the subject has a suspected or confirmed inflammatory condition.
• the effective amount is a prophylatically effective amount.
• the method prevents or reduces the likelihood of an inflammatory condition, e.g., in certain embodiments, the method comprises administering a macrolide of the present invention to a subject in need thereof in an amount sufficient to prevent or reduce the likelihood of an inflammatory condition.
• the subject is at risk to an inflammatory condition.
• an in vitro method of treating an inflammatory condition comprising contacting an effective amount of the macrolide of the present invention with an inflammatory cell culture.
• the term“inflammatory condition” refers to those diseases, disorders, or conditions that are characterized by signs of pain (dolor, from the generation of noxious substances and the stimulation of nerves), heat (calor, from vasodilatation), redness (rubor, from vasodilatation and increased blood flow), swelling (tumor, from excessive inflow or restricted outflow of fluid), and/or loss of function (functio laesa, which can be partial or complete, temporary or permanent).
• Inflammation takes on many forms and includes, but is not limited to, acute, adhesive, atrophic, catarrhal, chronic, cirrhotic, diffuse, disseminated, exudative, fibrinous, fibrosing, focal, granulomatous, hyperplastic, hypertrophic, interstitial, metastatic, necrotic, obliterative, parenchymatous, plastic, productive, proliferous, pseudomembranous, purulent, sclerosing, seroplastic, serous, simple, specific, subacute, suppurative, toxic, traumatic, and/or ulcerative inflammation.
• Exemplary inflammatory conditions include, but are not limited to, chronic pulmonary inflammatory syndromes (e.g., diffuse panbronchiolitis, cystic fibrosis, asthma, bronchiectasis, chronic obstructive pulmonary disease).
• chronic pulmonary inflammatory syndromes e.g., diffuse panbronchiolitis, cystic fibrosis, asthma, bronchiectasis, chronic obstructive pulmonary disease.
• the inflammatory condition is an acute inflammatory condition (e.g., for example, inflammation resulting from an infection).
• an acute inflammatory condition e.g., for example, inflammation resulting from an infection.
• the inflammatory condition is a chronic inflammatory condition. In certain embodiments, the inflammatory condition is inflammation associated with cancer.
• Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers.
• the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
• Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
• HPLC high pressure liquid chromatography
• the invention additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.
• structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, replacement of 19 F with 18 F, or the replacement of 12 C with 13 C or 14 C are within the scope of the disclosure.
• Such compounds are useful, for example, as analytical tools or probes in biological assays.
• C 1-6 alkyl is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 alkyl.
• aliphatic refers to alkyl, alkenyl, alkynyl, and carbocyclic groups.
• heteroaliphatic refers to heteroalkyl, heteroalkenyl, heteroalkynyl, and heterocyclic groups.
• alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 10 carbon atoms (“C 1-10 alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C 1-9 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1-8 alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1-7 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1-6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1-5 alkyl”).
• an alkyl group has 1 to 4 carbon atoms (“C 1-4 alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1-3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C 1-2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C 1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C 2-6 alkyl”).
• C 1-6 alkyl groups include methyl (C 1 ), ethyl (C 2 ), propyl (C 3 ) (e.g., n-propyl, isopropyl), butyl (C 4 ) (e.g., n-butyl, tert-butyl, sec-butyl, iso-butyl), pentyl (C 5 ) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), and hexyl (C 6 ) (e.g., n-hexyl).
• alkyl groups include n-heptyl (C 7 ), n- octyl (C 8 ), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an“unsubstituted alkyl”) or substituted (a“substituted alkyl”) with one or more substituents (e.g., halogen, such as F).
• substituents e.g., halogen, such as F
• the alkyl group is an unsubstituted C 1-10 alkyl (such as unsubstituted C 1-6 alkyl, e.g., ⁇ CH 3 (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (n-Bu), unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl (sec-Bu), unsubstituted isobutyl (i-Bu)).
• the alkyl group is a substituted C 1-10 alkyl (such as substituted C 1-6 alkyl, e.g., ⁇ CH 3 (Me), un
• haloalkyl is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo.
• the haloalkyl moiety has 1 to 8 carbon atoms (“C 1-8 haloalkyl”).
• the haloalkyl moiety has 1 to 6 carbon atoms (“C 1-6 haloalkyl”).
• the haloalkyl moiety has 1 to 4 carbon atoms (“C 1-4 haloalkyl”).
• the haloalkyl moiety has 1 to 3 carbon atoms (“C 1-3 haloalkyl”). In some embodiments, the haloalkyl moiety has 1 to 2 carbon atoms (“C 1-2 haloalkyl”). Examples of haloalkyl groups include ⁇ CF 3 , ⁇ CF 2 CF 3 , ⁇ CF 2 CF 2 CF 3 , ⁇ CCl 3 , ⁇ CFCl 2 , ⁇ CF 2 Cl, and the like.
• heteroalkyl refers to an alkyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain.
• a heteroalkyl group refers to a saturated group having from 1 to 10 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC 1-10 alkyl”).
• a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1 or more heteroatoms within the parent chain
• heteroC 1-9 alkyl (“heteroC 1-9 alkyl”).
• a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC 1-8 alkyl”).
• a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC 1-7 alkyl”).
• a heteroalkyl group is a saturated group having 1 to 6 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC 1-6 alkyl”).
• a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC 1-5 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1or 2 heteroatoms within the parent chain (“heteroC 1-4 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom within the parent chain (“heteroC 1-3 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom within the parent chain (“heteroC 1-2 alkyl”).
• a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“heteroC 1 alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC 2-6 alkyl”). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an“unsubstituted heteroalkyl”) or substituted (a“substituted heteroalkyl”) with one or more substituents. In certain
• the heteroalkyl group is an unsubstituted heteroC 1-10 alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroC 1-10 alkyl.
• alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds).
• an alkenyl group has 2 to 9 carbon atoms (“C 2-9 alkenyl”).
• an alkenyl group has 2 to 8 carbon atoms (“C 2-8 alkenyl”).
• an alkenyl group has 2 to 7 carbon atoms (“C 2-7 alkenyl”).
• an alkenyl group has 2 to 6 carbon atoms (“C 2-6 alkenyl”).
• an alkenyl group has 2 to 5 carbon atoms (“C 2-5 alkenyl”).
• an alkenyl group has 2 to 4 carbon atoms (“C 2-4 alkenyl”). In some
• an alkenyl group has 2 to 3 carbon atoms (“C 2-3 alkenyl”). In some
• an alkenyl group has 2 carbon atoms (“C 2 alkenyl”).
• the one or more carbon- carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
• Examples of C 2-4 alkenyl groups include ethenyl (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1- butenyl (C 4 ), 2-butenyl (C 4 ), butadienyl (C 4 ), and the like.
• C 2-6 alkenyl groups include the aforementioned C 2-4 alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. Additional examples of alkenyl include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 ), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an“unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents.
• heteroalkenyl refers to an alkenyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain.
• a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-10 alkenyl”).
• a heteroalkenyl group has 2 to 9 carbon atoms at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-9 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-8 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-7 alkenyl”).
• a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-6 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2-5 alkenyl”). In some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and 1or 2
• heteroatoms within the parent chain (“heteroC 2-4 alkenyl”).
• a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom within the parent chain (“heteroC 2-3 alkenyl”).
• a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2-6 alkenyl”).
• each instance of a heteroalkenyl group is independently unsubstituted (an“unsubstituted heteroalkenyl”) or substituted (a “substituted heteroalkenyl”) with one or more substituents.
• the heteroalkenyl group is an unsubstituted heteroC 2-10 alkenyl.
• the heteroalkenyl group is a substituted heteroC 2-10 alkenyl.
• alkynyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) (“C 2-10 alkynyl”). In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C 2-9 alkynyl”). In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C 2-8 alkynyl”). In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C 2- 7 alkynyl”).
• an alkynyl group has 2 to 6 carbon atoms (“C 2-6 alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2-5 alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C 2-4 alkynyl”). In some
• an alkynyl group has 2 to 3 carbon atoms (“C 2-3 alkynyl”). In some
• an alkynyl group has 2 carbon atoms (“C 2 alkynyl”).
• the one or more carbon- carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl).
• Examples of C 2-4 alkynyl groups include, without limitation, ethynyl (C 2 ), 1-propynyl (C 3 ), 2- propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ), and the like.
• Examples of C 2-6 alkenyl groups include the aforementioned C 2-4 alkynyl groups as well as pentynyl (C 5 ), hexynyl (C 6 ), and the like.
• alkynyl examples include heptynyl (C 7 ), octynyl (C 8 ), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an“unsubstituted alkynyl”) or substituted (a“substituted alkynyl”) with one or more substituents. In certain embodiments, the alkynyl group is an unsubstituted C 2-10 alkynyl. In certain embodiments, the alkynyl group is a substituted C 2-10 alkynyl.
• heteroalkynyl refers to an alkynyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain.
• a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-10 alkynyl”).
• a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-9 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2- 8 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-7 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC 2-6 alkynyl”). In some
• a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2-5 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and 1or 2 heteroatoms within the parent chain (“heteroC 2-4 alkynyl”). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom within the parent chain (“heteroC 2-3 alkynyl”).
• a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC 2-6 alkynyl”). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an“unsubstituted heteroalkynyl”) or substituted (a“substituted heteroalkynyl”) with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC 2-10 alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC 2-10 alkynyl.
• carbocyclyl or“carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 14 ring carbon atoms (“C 3-14 carbocyclyl”) and zero heteroatoms in the non-aromatic ring system.
• a carbocyclyl group has 3 to 10 ring carbon atoms (“C 3-10 carbocyclyl”).
• a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3-8 carbocyclyl”).
• a carbocyclyl group has 3 to 7 ring carbon atoms (“C 3-7 carbocyclyl”).
• a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms (“C 4-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms (“C 5-6 carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 carbocyclyl”).
• Exemplary C 3-6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ), cyclopropenyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
• Exemplary C 3-8 carbocyclyl groups include, without limitation, the aforementioned C 3-6 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptanyl (C 7 ), bicyclo[2.2.2]octanyl (C 8 ), and the like.
• Exemplary C 3-10 carbocyclyl groups include, without limitation, the aforementioned C 3-8 carbocyclyl groups as well as cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C 9 ), decahydronaphthalenyl (C 10 ),
• the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds.
• “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system.
• each instance of a carbocyclyl group is independently unsubstituted (an“unsubstituted carbocyclyl”) or substituted (a“substituted carbocyclyl”) with one or more substituents.
• the carbocyclyl group is an unsubstituted C 3-14 carbocyclyl.
• the carbocyclyl group is a substituted C 3-14 carbocyclyl.
• “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 14 ring carbon atoms (“C 3-14 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ring carbon atoms (“C 3-10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3-8 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3-6 cycloalkyl”).
• a cycloalkyl group has 4 to 6 ring carbon atoms (“C 4-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5-6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5-10 cycloalkyl”). Examples of C 5-6 cycloalkyl groups include cyclopentyl (C 5 ) and cyclohexyl (C 5 ).
• C 3-6 cycloalkyl groups include the aforementioned C 5-6 cycloalkyl groups as well as cyclopropyl (C 3 ) and cyclobutyl (C 4 ).
• Examples of C 3-8 cycloalkyl groups include the aforementioned C 3-6 cycloalkyl groups as well as cycloheptyl (C 7 ) and cyclooctyl (C 8 ).
• each instance of a cycloalkyl group is independently unsubstituted (an“unsubstituted cycloalkyl”) or substituted (a“substituted cycloalkyl”) with one or more substituents.
• the cycloalkyl group is an unsubstituted C 3-14 cycloalkyl.
• the cycloalkyl group is a substituted C 3-14 cycloalkyl.
• heterocyclyl or“heterocyclic” refers to a radical of a 3- to 14- membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3-14 membered heterocyclyl”).
• the point of attachment can be a carbon or nitrogen atom, as valency permits.
• a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon- carbon double or triple bonds.
• Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings.“Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
• each instance of heterocyclyl is independently unsubstituted (an“unsubstituted heterocyclyl”) or substituted (a“substituted heterocyclyl”) with one or more substituents.
• the heterocyclyl group is an unsubstituted 3-14 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3-14 membered heterocyclyl.
• a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heterocyclyl”).
• a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”).
• a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”).
• the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
• Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, and thiiranyl.
• Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl, and thietanyl.
• Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl,
• Exemplary 5- membered heterocyclyl groups containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl.
• Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
• Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
• Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, triazinanyl. Exemplary 7- membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1
• heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
• Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8- naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, n
• aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C 6-14 aryl”).
• aromatic ring system e.g., having 6, 10, or 14 pi electrons shared in a cyclic array
• an aryl group has 6 ring carbon atoms (“C 6 aryl”; e.g., phenyl).
• an aryl group has 10 ring carbon atoms (“C 10 aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl).
• an aryl group has 14 ring carbon atoms (“C 14 aryl”; e.g., anthracyl).“Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
• each instance of an aryl group is independently unsubstituted (an“unsubstituted aryl”) or substituted (a“substituted aryl”) with one or more substituents.
• the aryl group is an unsubstituted C 6-14 aryl. In certain embodiments, the aryl group is a substituted C 6-14 aryl.
• Alkyl is a subset of“alkyl” and refers to an alkyl group substituted by an aryl group, wherein the point of attachment is on the alkyl moiety.
• heteroaryl refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-14 membered heteroaryl”).
• the point of attachment can be a carbon or nitrogen atom, as valency permits.
• Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings.“Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system.
• Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system.
• Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
• the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl).
• a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”).
• a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”).
• a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”).
• the 5- 6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
• each instance of a heteroaryl group is independently unsubstituted (an“unsubstituted heteroaryl”) or substituted (a“substituted heteroaryl”) with one or more substituents.
• the heteroaryl group is an unsubstituted 5-14 membered heteroaryl.
• the heteroaryl group is a substituted 5-14 membered heteroaryl.
• Exemplary 5-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyrrolyl, furanyl, and thiophenyl.
• Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
• Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
• Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include, without limitation, tetrazolyl.
• Exemplary 6-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyridinyl.
• Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
• Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
• Exemplary 7-membered heteroaryl groups containing 1 heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
• Exemplary 5,6- bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl,
• Exemplary 6,6-bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
• Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl and phenazinyl.
• Heteroaralkyl is a subset of“alkyl” and refers to an alkyl group substituted by a heteroaryl group, wherein the point of attachment is on the alkyl moiety.
• alkylene is the divalent moiety of alkyl
• alkenylene is the divalent moiety of alkenyl
• alkynylene is the divalent moiety of alkynyl
• heteroalkylene is the divalent moiety of heteroalkyl
• heteroalkenylene is the divalent moiety of heteroalkenyl
• heteroalkynylene is the divalent moiety of heteroalkynyl
• carbocyclylene is the divalent moiety of carbocyclyl
• heterocyclylene is the divalent moiety of heterocyclyl
• arylene is the divalent moiety of aryl
• heteroarylene is the divalent moiety of heteroaryl.
• a group is optionally substituted unless expressly provided otherwise.
• the term “optionally substituted” refers to being substituted or unsubstituted.
• alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted.
• “Optionally substituted” refers to a group which may be substituted or unsubstituted (e.g.,“substituted” or“unsubstituted” alkyl, “substituted” or“unsubstituted” alkenyl,“substituted” or“unsubstituted” alkynyl, “substituted” or“unsubstituted” heteroalkyl,“substituted” or“unsubstituted” heteroalkenyl, “substituted” or“unsubstituted”
• the term“substituted” means that at least one hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
• a“substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
• substituted is contemplated to include substitution with all permissible substituents of organic compounds, and includes any of the substituents described herein that results in the formation of a stable compound.
• the present invention contemplates any and all such combinations in order to arrive at a stable compound.
• heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
• the invention is not intended to be limited in any manner by the exemplary substituents described herein.
• Exemplary carbon atom substituents include, but are not limited to, halogen, ⁇ CN, ⁇ NO 2 , ⁇ N 3 , ⁇ SO 2 H, ⁇ SO 3 H, ⁇ OH, ⁇ OR aa , ⁇ ON(R bb ) 2 , ⁇ N(R bb ) 2 , ⁇ N(R bb ) +
• R aa is, independently, selected from C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R aa groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alken
• each instance of R cc is, independently, selected from hydrogen, C 1-10 alkyl, C 1-10 perhaloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroC 1-10 alkyl, heteroC 2-10 alkenyl, heteroC 2-10 alkynyl, C 3-10 carbocyclyl, 3-14 membered heterocyclyl, C 6-14 aryl, and 5-14 membered heteroaryl, or two R cc groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;
• each instance of R dd is, independently, selected from halogen, ⁇ CN, ⁇ NO 2 , ⁇ N 3 , ⁇ SO 2 H, ⁇ SO 3 H, ⁇ OH, ⁇ OR ee , ⁇ ON(R ff ) 2 , ⁇ N(R ff ) 2 , ⁇ N(R ff ) +
• each instance of R ee is, independently, selected from C 1-6 alkyl, C 1-6 perhaloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, heteroC 1 _ 6 alkyl, heteroC 2 _ 6 alkenyl, heteroC 2 _ 6 alkynyl, C 3 _io carbocyclyl, C 6-1 o aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;
• each instance of R ff is, independently, selected from hydrogen, C 1 _ 6 alkyl, C 1 _ 6 perhaloalkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, heteroC 1 _ 6 alkyl, heteroC 2 _ 6 alkenyl, heteroC 2 _ 6 alkynyl, C 3 _io carbocyclyl, 3-10 membered heterocyclyl, C 6-1 o aryl and 5-10 membered heteroaryl, or two R ff groups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
• heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups;
• halo refers to fluorine (fluoro, ⁇ F), chlorine (chloro, ⁇ Cl), bromine (bromo, ⁇ Br), or iodine (iodo, ⁇ I).
• hydroxyl refers to the group ⁇ OH.
• amino refers to the group ⁇ NH 2 .
• substituted amino by extension, refers to a monosubstituted amino, a disubstituted amino, or a trisubstituted amino. In certain embodiments, the“substituted amino” is a monosubstituted amino or a
• trisubstituted amino refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with three groups, and includes groups selected from ⁇ N(R bb ) 3 and ⁇ N(R bb ) +
• sulfonyl refers to a group selected from ⁇ SO 2 N(R bb ) 2 , ⁇ SO 2 R aa , and ⁇ SO 2 OR aa , wherein R aa and R bb are as defined herein.
• heteroaliphatic cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy,
• heteroaryloxy aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or di- aliphaticamino, mono- or di- heteroaliphaticamino, mono- or di- alkylamino, mono- or di- heteroalkylamino, mono- or di-arylamino, or mono- or di-heteroarylamino; or two R X1 groups taken together form a 5- to 6-membered heterocyclic ring.
• acyl groups include aldehydes ( ⁇ CHO), carboxylic acids ( ⁇ CO 2 H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas.
• Acyl substituents include, but are not limited to, any of the substituents described herein, that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyl
• sil refers to the group ⁇ Si(R aa ) 3 , wherein R aa is as defined herein.
• Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms.
• the substituent present on the nitrogen atom is an nitrogen protecting group (also referred to herein as an“amino protecting group”).
• heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups, and wherein R aa , R bb , R cc and R dd are as defined herein.
• Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
• Nitrogen protecting groups such as carbamate groups include, but are not limited to, methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD- Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2- trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1- methyle
• Nitrogen protecting groups such as sulfonamide groups include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6- dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4- methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6- trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanes
• Ts p-toluenesulfonamide
• Mtr 2,
• nitrogen protecting groups include, but are not limited to, phenothiazinyl- (10)-acyl derivative, N’-p-toluenesulfonylaminoacyl derivative, N’-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3- oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5- dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5- substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5- triazacyclohexan-2-one, 1-substituted 3,5-di
• Dpp diphenylphosphinamide
• Mpt dimethylthiophosphinamide
• diphenylthiophosphinamide Ppt
• dialkyl phosphoramidates dibenzyl phosphoramidate, diphenyl phosphoramidate
• benzenesulfenamide o-nitrobenzenesulfenamide
• Nps 2,4- dinitrobenzenesulfenamide
• pentachlorobenzenesulfenamide 2-nitro-4- methoxybenzenesulfenamide
• triphenylmethylsulfenamide triphenylmethylsulfenamide
• 3-nitropyridinesulfenamide Npys
• the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as an“hydroxyl protecting group”).
• Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
• oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl,
• DEIPS diethylisopropylsilyl
• TDMS t-butyldimethylsilyl
• TDPS t- butyldiphenylsilyl
• tribenzylsilyl tri-p-xylylsilyl, triphenylsilyl
• DPMS diphenylmethylsilyl
• TMPS t-butylmethoxyphenylsilyl
• formate benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4- oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6- trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate
• the substituent present on an sulfur atom is a sulfur protecting group (also referred to as a“thiol protecting group”).
• Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
• a“leaving group” is an art-understood term referring to a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage, wherein the molecular fragment is an anion or neutral molecule.
• a leaving group can be an atom or a group capable of being displaced by a nucleophile. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501-502).
• the leaving group is a halogen.
• the leaving group is I.
• phrase“at least one instance” refers to 1, 2, 3, 4, or more instances, but also encompasses a range, e.g., for example, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 4, from 2 to 3, or from 3 to 4 instances, inclusive.
• A“non-hydrogen group” refers to any group that is defined for a particular variable that is not hydrogen.
• carbohydrate refers to an aldehydic or ketonic derivative of polyhydric alcohols.
• Carbohydrates include compounds with relatively small molecules (e.g., sugars) as well as macromolecular or polymeric substances (e.g., starch, glycogen, and cellulose polysaccharides).
• saccharide refers to monosaccharides, disaccharides, or polysaccharides. Monosaccharides are the simplest carbohydrates in that they cannot be hydrolyzed to smaller carbohydrates.
• monosaccharides can be represented by the general formula C y H 2y O y (e.g., C 6 H 12 O 6 (a hexose such as glucose)), wherein y is an integer equal to or greater than 3.
• C y H 2y O y e.g., C 6 H 12 O 6 (a hexose such as glucose)
• y is an integer equal to or greater than 3.
• Certain polyhydric alcohols not represented by the general formula described above may also be considered monosaccharides.
• deoxyribose is of the formula C 5 H 10 O 4 and is a monosaccharide.
• Monosaccharides usually consist of five or six carbon atoms and are referred to as pentoses and hexoses, receptively.
• the monosaccharide contains an aldehyde it is referred to as an aldose; and if it contains a ketone, it is referred to as a ketose.
• Monosaccharides may also consist of three, four, or seven carbon atoms in an aldose or ketose form and are referred to as trioses, tetroses, and heptoses, respectively.
• Glyceraldehyde and dihydroxyacetone are considered to be aldotriose and ketotriose sugars, respectively.
• aldotetrose sugars include erythrose and threose
• ketotetrose sugars include erythrulose.
• Aldopentose sugars include ribose, arabinose, xylose, and lyxose; and ketopentose sugars include ribulose, arabulose, xylulose, and lyxulose.
• aldohexose sugars include glucose (for example, dextrose), mannose, galactose, allose, altrose, talose, gulose, and idose; and ketohexose sugars include fructose, psicose, sorbose, and tagatose.
• Ketoheptose sugars include sedoheptulose.
• the aldohexose D -glucose for example, has the formula C 6 H 12 O 6 , of which all but two of its six carbons atoms are stereogenic, making D-glucose one of the 16 (i.e., 2 4 ) possible stereoisomers.
• the assignment of D or L is made according to the orientation of the asymmetric carbon furthest from the carbonyl group: in a standard Fischer projection if the hydroxyl group is on the right the molecule is a D sugar, otherwise it is an L sugar.
• the aldehyde or ketone group of a straight- chain monosaccharide will react reversibly with a hydroxyl group on a different carbon atom to form a hemiacetal or hemiketal, forming a heterocyclic ring with an oxygen bridge between two carbon atoms. Rings with five and six atoms are called furanose and pyranose forms, respectively, and exist in equilibrium with the straight-chain form.
• the carbon atom containing the carbonyl oxygen becomes a stereogenic center with two possible configurations: the oxygen atom may take a position either above or below the plane of the ring.
• the resulting possible pair of stereoisomers is called anomers.
• an ⁇ anomer the ⁇ OH substituent on the anomeric carbon rests on the opposite side (trans) of the ring from the ⁇ CH 2 OH side branch.
• the alternative form, in which the ⁇ CH 2 OH substituent and the anomeric hydroxyl are on the same side (cis) of the plane of the ring, is called a ⁇ anomer.
• a carbohydrate including two or more joined monosaccharide units is called a disaccharide or polysaccharide (e.g., a trisaccharide), respectively.
• Exemplary disaccharides include sucrose, lactulose, lactose, maltose, isomaltose, trehalose, cellobiose, xylobiose, laminaribiose, gentiobiose, mannobiose, melibiose, nigerose, or rutinose.
• Exemplary trisaccharides include, but are not limited to, isomaltotriose, nigerotriose, maltotriose, melezitose, maltotriulose, raffinose, and kestose.
• carbohydrate also includes other natural or synthetic stereoisomers of the carbohydrates described herein.
• salt refers to any and all salts, and encompasses pharmaceutically acceptable salts.
• pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
• Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
• Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
• suitable inorganic and organic acids and bases include those derived from suitable inorganic and organic acids and bases.
• pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
• salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate,
• salts derived from appropriate bases include alpha-1-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
• Salts derived from appropriate bases include alpha-1-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanes
• Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
• Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
• solvate refers to forms of the compound, or a salt thereof, that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding.
• solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like.
• the compounds described herein may be prepared, e.g., in crystalline form, and may be solvated. Suitable solvates include
• solvates and further include both stoichiometric solvates and non-stoichiometric solvates.
• the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid.“Solvate” encompasses both solution-phase and isolatable solvates.
• Representative solvates include hydrates, ethanolates, and methanolates.
• hydrate refers to a compound that is associated with water.
• the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R ⁇ x H 2 O, wherein R is the compound, and x is a number greater than 0.
• a given compound may form more than one type of hydrate, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5 H 2 O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6 H 2 O)).
• monohydrates x is 1
• lower hydrates x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5 H 2 O)
• polyhydrates x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6 H 2 O)
• tautomers or“tautomeric” refers to two or more interconvertable compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa).
• the exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base.
• Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.
• enantiomers and those that are non-superimposable mirror images of each other are termed“enantiomers”.
• An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or ( ⁇ )-isomers respectively).
• a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
• polymorph refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof). All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.
• prodrugs refers to compounds that have cleavable groups and become by solvolysis or under physiological conditions the compounds described herein, which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like. Other derivatives of the compounds described herein have activity in both their acid and acid derivative forms, but in the acid sensitive form often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp.7-9, 21-24, Elsevier, Amsterdam 1985).
• Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds described herein are particular prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
• C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, aryl, C 7 -C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds described herein may be preferred.
• composition and“formulation” are used interchangeably.
• A“subject” to which administration is contemplated refers to a human (i.e., male or female of any age group, e.g., pediatric subject (e.g., infant, child, or adolescent) or adult subject (e.g., young adult, middle-aged adult, or senior adult)) or non-human animal.
• the non-human animal is a mammal (e.g., primate (e.g., cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g., cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g., commercially relevant bird, such as chicken, duck, goose, or turkey)).
• primate e.g., cynomolgus monkey or rhesus monkey
• commercially relevant mammal e.g., cattle, pig, horse, sheep, goat, cat, or dog
• bird e.g., commercially relevant bird, such as
• the non-human animal is a fish, reptile, or amphibian.
• the non-human animal may be a male or female at any stage of development.
• the non-human animal may be a transgenic animal or genetically engineered animal“Disease,”“disorder,” and“condition” are used interchangeably herein.
• administer refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, in or on a subject.
• the terms“treat,”“treating” and “treatment” contemplate an action that occurs while a subject is suffering from the specified infectious disease or inflammatory condition, which reduces the severity of the infectious disease or inflammatory condition, or retards or slows the progression of the infectious disease or inflammatory condition (“therapeutic treatment”), and also contemplates an action that occurs before a subject begins to suffer from the specified infectious disease or inflammatory condition (“prophylactic treatment”).
• the“effective amount” of a compound refers to an amount sufficient to elicit the desired biological response.
• the effective amount of a compound of the invention may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and condition of the subject.
• An effective amount encompasses therapeutic and prophylactic treatment.
• a“therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of an infectious disease or inflammatory condition, or to delay or minimize one or more symptoms associated with the infectious disease or inflammatory condition.
• a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the infectious disease or inflammatory condition.
• the term“therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of infectious disease or inflammatory condition, or enhances the therapeutic efficacy of another therapeutic agent.
• a“prophylactically effective amount” of a compound is an amount sufficient to prevent an infectious disease or inflammatory condition, or one or more symptoms associated with the infectious disease or inflammatory condition, or prevent its recurrence.
• a prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the infectious disease or inflammatory condition.
• the term“prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
• the term“inflammatory disease” refers to a disease caused by, resulting from, or resulting in inflammation.
• the term“inflammatory disease” may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and/or T-lymphocytes leading to abnormal tissue damage and/or cell death.
• An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non-infectious causes.
• Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory arthritis, Sjogren’s syndrome, giant cell arteritis, progressive systemic sclerosis
• the macrolide antibiotics inhibit peptide synthesis by hindering transit of the nascent peptide through the exit tunnel in the bacterial ribosome.
• telithromycin and solithromycin are believed to engage in pi-stacking interactions with the A752-U2609 base pair, enhancing binding to the ribosome. See, e.g., Mankin, Curr. Opin. Microbiol.2008, 11, 414-421;
• the fluorine atom at position C2 of solithromycin makes a hydrophobic contact with C2611, and is believed to account for the 4- to 16-fold increase in activity versus the non-fluorinated molecule against panels of Gram-positive bacteria. See, e.g., Llano-Sotelo et al., Antimicrob. Agents Chemother.2010, 54, 4961-4970.
• Modification of the macrolide binding pocket is one of the primary forms of resistance among pathogenic bacteria. This can take the form of a base modification (e.g., A2058 dimethylation by erm genes), a base mutation (e.g., A2058G, A2059G, C2611G), or a more subtle alteration of the binding pocket caused by distal mutations in the ribosome (e.g., L4 ribosomal peptide modification). See, e.g., Leclercq et al., Antimicrob. Agents Chemother. 1991, 35, 1273-1276; Leclercq et al., Antimicrob.
• the method comprises the synthesis of eastern half and western half precursors to the macrolide which are independently synthesized as fragments of similar complexity.
• the synthesis typically converges with coupling of the eastern and western halves, and macrolactonization to form the 14, 15, or 16 membered macrolide ring.
• a diverse range of substituents at various ring positions can be introduced during synthesis of the separate halves, after coupling but before lactonization, or after both coupling and lactonization, or a combination thereof.
• Azido sugar 9 was converted to the protected thioglycoside in two additional steps. Treatment with acetic anhydride quantitatively converts the anomeric methoxy position to acetoxy.
• the acetoxy group of 10 is a suitable leaving group for thioglycosidation, which was carried out with mercaptopyrimidine, trimethylsilyl triflate and 2,6-lutidine to yield thioglycoside 11 in 68% yield.
• Preparation of the eastern half of a 6-azido-D-desosamine analog (15).
• 6'-azido-macrolide 19 (10 mg, 9.73 ⁇ mol) was dissolved in tBuOH/methanol/water (2:2:1, 0.5 mL).2-ethynylpyridine (2.008 mg, 0.019 mmol), sodium ascorbate (0.1 M in water, 19.47 ⁇ l, 1.947 ⁇ mol), and copper(II) sulfate (0.1 M in water, 4.87 ⁇ l, 0.487 ⁇ mol) were added sequentially. The reaction was stirred at 23 oC for 16 hours, at which point LC- MS showed full conversion and full deprotection of the methyl carbonate.
• the reaction mixture was diluted with dichloromethane (2 mL) and saturated aqueous sodium bicarbonate solution (1 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (3 x 2 mL). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by column chromatography (3 ⁇ 5% methanol ⁇ dichloromethane + 0.3 ⁇ 0.5% saturated aqueous ammonium hydroxide solution) to give the product (20) as a colorless film (7.8 mg, 75%).
• Dess–Martin periodinane (148 mg, 0.349 mmol, 1.50 equiv) was added in one portion to a solution of alcohol S26 (150 mg, 0.233 mmol, 1 equiv) in water-saturated dichloromethane (1.2 mL) at 23 °C. After 1 h, to the reaction mixture was added ether (10 mL), saturated aqueous sodium bicarbonate solution (5 mL) and saturated sodium thiosulfate solution (5 mL). The mixture was stirred vigorously for 15 min. The layers were separated and the aqueous layer was extracted with ether (2 ⁇ 10 mL). The combined ether layers were washed with brine and dried over magnesium sulfate.
• Macrocyclization precursor 254 (135 mg, 0.146 mmol) was dissolved in chlorobenzene (146 mL) in a 250-mL flask. The flask was fitted with a dry reflux condenser. Dry argon was bubbled through the solution via a 19-gauge needle for 10 min. The flask was then immersed in a 150-°C oil bath to allow a gentle reflux of the reaction solution. After 16 h, the heating bath was removed and the solution was allowed to cool to 23 °C.
• Tetrakis(triphenylphosphine)palladium(0) (1.7 mg, 1.5 ⁇ mol, 0.020 equiv) and tri- n-butyltinhydride (40 ⁇ L, 0.15 mmol, 2.0 equiv) were added sequentially to a solution of macrocycle 256 (77 mg, 0.075 mmol, 1 equiv) and acetic acid (21 ⁇ L, 0.38 mmol, 5.0 equiv) in THF (0.75 mL) at 23 °C. The reaction mixture was stirred for 1 h at 23 °C and then partitioned between ethyl ether (5 mL) and water (5 mL).

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Tropical Medicine & Parasitology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=56977809

Family Applications (1)

Country Status (7)

Cited By (5)

Families Citing this family (1)

Citations (3)

Family Cites Families (63)

• 2016
  • 2016-03-25 EP EP16769811.7A patent/EP3273969A4/en not_active Withdrawn
  • 2016-03-25 JP JP2017550153A patent/JP2018509452A/ja active Pending
  • 2016-03-25 US US15/558,896 patent/US10640528B2/en active Active
  • 2016-03-25 CA CA2980315A patent/CA2980315A1/en not_active Abandoned
  • 2016-03-25 WO PCT/US2016/024333 patent/WO2016154591A1/en not_active Ceased
  • 2016-03-25 CN CN201680028253.7A patent/CN107530365A/zh active Pending
  • 2016-03-25 HK HK18109724.4A patent/HK1250371A1/zh unknown
• 2020
  • 2020-04-08 US US16/843,017 patent/US11535643B2/en active Active

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events